EP1999264B1 - Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids - Google Patents

Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids Download PDF

Info

Publication number
EP1999264B1
EP1999264B1 EP07727304A EP07727304A EP1999264B1 EP 1999264 B1 EP1999264 B1 EP 1999264B1 EP 07727304 A EP07727304 A EP 07727304A EP 07727304 A EP07727304 A EP 07727304A EP 1999264 B1 EP1999264 B1 EP 1999264B1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
acid
seq
coa
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07727304A
Other languages
German (de)
French (fr)
Other versions
EP1999264A2 (en
Inventor
Roland H. MÜLLER
Thore Rohwerder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Roehm GmbH
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Publication of EP1999264A2 publication Critical patent/EP1999264A2/en
Application granted granted Critical
Publication of EP1999264B1 publication Critical patent/EP1999264B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/40Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42Hydroxy-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/40Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52Propionic acid; Butyric acids

Definitions

  • the present invention relates to a process for the enzymatic preparation of 2-hydroxy-2-methylcarboxylic acids from 3-hydroxycarboxylic acids, wherein a 3-hydroxycarboxylic acid is produced in an aqueous reaction solution and / or added to this reaction solution and incubated.
  • the aqueous reaction solution contains a 3-hydroxycarboxylic acid CoA mutase activity unit having both 3-hydroxycarbonyl-CoA ester producing and 3-hydroxycarbonyl-CoA ester isomerizing activity and converting the 3-hydroxycarboxylic acid to the corresponding 2 -Hydroxy-2-methylcarboxylic acid, which is obtained as acid or in the form of its salts.
  • the 3-hydroxycarboxylic acid CoA mutase activity-comprising moiety comprises an isolated cobalamin-dependent mutase and optionally a 3-hydroxycarbonyl-CoA ester-producing enzyme or enzyme system or is a microorganism containing it.
  • the invention relates to a biotechnological process for the production of 2-hydroxy-2-methylcarboxylic acids, wherein microorganisms having the desired mutase activity are cultured in an aqueous system with the aid of simple natural substances and intracellularly formed 3-hydroxycarbonyl-CoA esters the corresponding 2-hydroxy-2-methylcarboxylic acids are converted.
  • the invention also includes the production of unsaturated 2-methylcarboxylic acids wherein the recovered 2-hydroxy-2-methylcarboxylic acids are converted by dehydration into the corresponding unsaturated 2-methylcarboxylic acids (methacrylic acid and higher homologs).
  • the strain HCM-10 (DSM 18028) is used as the 3-hydroxycarbonyl-CoA thioester-producing and 3-hydroxycarbonyl-CoA thioester isomerizing microorganism.
  • Methacrylic acid as well as homologous unsaturated 2-methylcarboxylic acids are widely used in the production of acrylic sheets, injection molded products, coatings and many other products.
  • An alternative method of producing methacrylic acid and its homologs is by hydrolysis of 2-hydroxynitriles to the corresponding 2-hydroxy-2-methylcarboxylic acids using nitrile-hydrolyzing enzymes. It is nitrilase or a combination of nitrile hydratase and amidase ( A. Banerjee, R. Sharma, UC Banerjee, 2002, "The nitrile-degrading enzymes: current status and future prospects", Appl. Microbiol. Biotechnol., 60: 33-44 ). This procedure is protected by several patents ( US Pat. No. 6,582,943 B1 ).
  • a serious disadvantage of this method is the instability of the nitriles in the neutral pH range required for efficient nitrile hydrolyzing enzyme activity.
  • the Decay of the nitriles in the reaction mixture leads to an accumulation of ketones and cyanide, both of which inhibit the nitrile-hydrolyzing enzyme activities.
  • the invention therefore an object of the invention to seek alternative ways to produce 2-hydroxy-2-methylcarboxylic acids and provide means and methods that are based on the application of simple, umunschunmticher reactants as possible, consume little energy and produce little waste.
  • the object is achieved by an enzymatic process for the preparation of 2-hydroxy-2-methylcarboxylic acids from 3-hydroxycarboxylic acids.
  • the 3-hydroxycarboxylic acid is produced in an aqueous reaction solution which has a 3-hydroxycarboxylic acid CoA mutase activity-containing unit, and / or added to such a reaction solution.
  • a unit comprising a 3-hydroxycarboxylic acid CoA mutase activity is understood as meaning a unit comprising a cobalamin-dependent mutase and optionally a 3-hydroxycarbonyl-CoA ester-producing enzyme or enzyme system or a biological system comprising or producing the same.
  • the invention relates to a biotechnological process for the production of 2-hydroxy-2-methylcarboxylic acids using microorganisms.
  • microorganisms usually have 3-hydroxycarbonyl-CoA-esters synthesizing activity and are able to produce such a cobalamin-dependent mutase or include such a mutase and are by the 3-hydroxycarboxylic acid-CoA mutase activity capable of intracellularly from simple natural products (starting materials, such as sugar and / or or alcohols and / or organic acids and their derivatives) converted 3-hydroxycarbonyl-CoA esters into the corresponding 2-hydroxy-2-methylcarbonyl-CoA ester.
  • starting materials such as sugar and / or or alcohols and / or organic acids and their derivatives
  • the process according to the invention is characterized in particular by the fact that microorganisms which produce the cobalamin-dependent mutase and have 3-hydroxycarboxylic acid-CoA mutase activity in aqueous systems for the conversion of 3-hydroxycarboxylic acids into the corresponding 2-hydroxy-2-one methylcarboxylic acid is used.
  • microorganisms comprising 3-hydroxycarboxylic acid CoA mutase activity and having both 3-hydroxycarbonyl-CoA thioester producing and 3-hydroxycarbonyl-CoA thioester isomerizing activity in an aqueous system with renewable resources or from Utilization of renewable raw materials resulting waste products as carbon and energy source cultivated.
  • the intracellularly formed 3-hydroxycarboxylic acid CoA thioesters are converted to the corresponding 2-hydroxy-2-methylcarboxylic acids.
  • the reaction takes place with the addition of external 3-hydroxycarboxylic acid.
  • the corresponding 2-hydroxy-2-methylcarboxylic acid is solubilized as acid or in the form of its salts.
  • This novel biotechnological process which utilizes the production of 3-hydroxycarboxylic acids from simple natural products and their isomerization to 2-hydroxy-2-methylcarboxylic acids, is capable of solving the above-mentioned problem.
  • reaction conditions pH, ion concentration, oxygen / carbon dioxide requirement, trace elements, temperatures and the like
  • the reaction conditions are of course chosen so that the microorganisms are capable of optimal conversion of 3-hydroxycarboxylic acids to 2-hydroxy-2-methylcarboxylic acids.
  • cell proliferation and thus an increase in mutase concentration may be possible under suitable conditions.
  • the enzymatic conversion by means of microorganisms may be a significant advantage in terms of reliability, automation and simplicity as well as quality and yield of the final product of the process.
  • the 3-hydroxycarboxylic acid CoA mutase activity possessing unit so a cobalamin-dependent mutase, preferably in combination with a CoA ester synthesizing activity, in purified, enriched and / or isolated form in the reaction solution, wherein the enzymes may be of natural origin, for example.
  • the enzymes may be recombinantly produced enzymes from a genetically engineered organism.
  • the enzymes are used in the novel process according to the invention as catalysts both in the form of intact microbial cells and in the form of permeabilized microbial cells.
  • Other uses exist in the form of components (one or more) of microbial cell extracts, but also in partially purified or purified form.
  • other CoA ester synthesizing enzymes e.g. CoA transferase or CoA synthetases, used according to the invention.
  • the enzymatic catalysts may be immobilized or attached to a dissolved or undissolved carrier material.
  • certain cell compartments or portions thereof are separated or pooled, that is, carbohydrate structures, lipids or proteins and / or peptides, as well as nucleic acids capable of positively or negatively affecting unit having mutase activity can be combined or be separated.
  • the microorganisms e.g. prepared crude extracts, which are optionally centrifuged in order to carry out an inventive reaction with the sediment or the supernatant can.
  • 3-hydroxycarboxylic acids such as 3-hydroxybutyric acid
  • their intracellular CoA thioesters 3-hydroxycarbonyl-CoA can be readily prepared by a large number of bacterial strains from simple natural products.
  • These acids are the building blocks / monomers for the widely-used bacterial carbon and energy storage material poly-3-hydroxyalkanoate.
  • Rearrangements of carbon within the skeleton of carboxylic acids are also widely used in bacterial as well as other biological systems. So far, however, no biological system for the conversion of 3-hydroxycarbonyl-CoA ester be detected in the corresponding 2-hydroxy-2-methylcarbonyl-CoA esters.
  • the invention is based on the surprising discovery that systems with cobalamin-dependent mutase activity have both properties.
  • Cobalamin-dependent mutases containing microorganisms are, for example, methylibium petroleiphilum PM1, methylibium sp. R8 (strain collection UFZ Stuttgart), the ⁇ proteobacterial strain HCM-10, Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614.
  • strain HCM-10 A preferred suitable biological system was found with strain HCM-10. It was deposited under the Budapest Treaty on the deposit of microorganisms for the purposes of patent procedures at the German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, DE under the number DSM 18028 on 13.03.2006.
  • microorganisms which on the one hand have the same gene or gene product or on the other hand have an analogous gene which leads to gene products with similar or analogous activity. That is, 3-hydroxycarbonyl-CoA mutase activities of other origin are also covered by the invention.
  • the invention includes transformed systems having a or a similar 3-hydroxycarbonyl-CoA mutase activity, such as strain HCM-10 or those of other origin. These may include mutants, genetically modified as well as isolated modifications of the microorganisms, eg organisms that have the desired cobalamin-dependent mutase activity due to the introduction of a mutase-encoding nucleotide sequence.
  • the preferred biological system used produces 3-hydroxycarbonyl-CoA esters as thioesters, from simple natural products such as sugars and / or organic acids and / or alcohols and derivatives thereof.
  • the 3-hydroxycarbonyl-CoA esters are converted to 2-hydroxy-2-methylcarbonyl-CoA ester by the cobalamin-dependent carbon skeleton transforming mutase, as exemplified in Equation 1 for the case of the ( R ) -3- Hydroxybutyryl-CoA is shown.
  • the CoA thioester is hydrolyzed in the system and the acid is eliminated in the culture medium.
  • the preferred enzyme catalysts for the process according to the invention are the cobalamin-dependent mutase-containing microorganism strains HCM-10 (DSM 18028), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614, their crude extracts or parts used.
  • the strains used according to the invention preferably produce the proteins having the sequences SEQ ID NO: 2 and / or SEQ ID NO: 4 or the nucleic acid sequences SEQ ID NO: 1 and / or SEQ ID NO: 3 (HCM-10) comprising the proteins with the sequences SEQ ID NO: 5 and / or SEQ ID NO: 6 or comprise the nucleic acid sequences SEQ ID NO: 7 and / or SEQ ID NO: 8 (Xanthobacter autotrophicus Py2), the proteins having the sequences SEQ ID NO: 9 and / or SEQ ID NO: 10 or comprise the nucleic acid sequences SEQ ID NO: 11 and / or SEQ ID NO: 12 (Rhodobacter sphaeroides ATCC 17029) or the proteins having the sequences SEQ ID NO: 13 and / or SEQ ID NO: 14 or comprise the nucleic acid sequences SEQ ID NO: 15 and / or SEQ ID NO: 16 (Nocardioides sp., JS614).
  • the enzyme catalysts in particular microorganisms, crude extracts, parts thereof and / or the enriched or isolated enzymes are immobilized. Immobilization places enzymes, cell organelles and cells in an insoluble and reaction-space limited state. For example, they can be immobilized in a polymer matrix (eg alginate, polyvinyl alcohol or polyacrylamide gels). Immobilization may also be carried out on dissolved or undissolved carrier materials (eg celite) to facilitate catalyst recovery and use. Methods for cell immobilization in a polymer matrix or on a dissolved or undissolved carrier are known to the person skilled in the art and have already been described in detail. The enzyme activities can also be isolated from the microbial cells.
  • a polymer matrix eg alginate, polyvinyl alcohol or polyacrylamide gels
  • Immobilization may also be carried out on dissolved or undissolved carrier materials (eg celite) to facilitate catalyst recovery and use.
  • the conversion of 3-hydroxycarboxylic acids into 2-hydroxy-2-methylcarboxylic acids is preferably carried out in the context of a continuous process which can be carried out in a reactor through which microbial growth and thus product formation take place.
  • a continuous process can also be understood to mean any system of growing cells and catalyzing enzymes to which nutrient solution is added on the one hand and from which, on the other hand, culture solution, including enzymatically formed 2-hydroxy-2-methylcarboxylic acid, is withdrawn.
  • the method can also be carried out as a semicontinuous or batch process.
  • the 3-hydroxycarboxylic acid which is the starting material for the 2-hydroxy-2-methylcarboxylic acid, is preferably prepared by enzymatic conversion of carbohydrates and / or organic acids and / or alcohols or derivatives thereof.
  • CoA-ester-synthesizing enzymes which are present or added in the microorganism become.
  • a substrate with a tert is used for culturing.
  • Butyl used as a carbon and energy source, preferably tert.
  • Butyl alcohol as the sole carbon and energy source in a basal medium.
  • the process according to the invention can preferably be used for the preparation of 2-hydroxy-2-methylpropanoic acid (2-hydroxyisobutyric acid).
  • the preferred preparation of 2-hydroxyisobutyric acid is further characterized in that externally 3-hydroxybutyric acid is added.
  • the process may be performed aerobically, preferably using whole cells, or anaerobically, e.g. under nitrogen, preferably when extracts or purified enzymes are used.
  • an enzyme according to the invention is preferably a heterodimeric protein which contains the enzymes described under Seq. No. 2 and Seq. No. 4 and thus has excellent enzyme activity.
  • a nucleic acid molecule may be a DNA molecule, preferably cDNA or genomic DNA and / or an RNA molecule. Both nucleic acids and proteins can be isolated from natural sources, preferably from DSM 18028, but also for example from Methylibium petroleiphilum PM1, Methylibium sp. R8 (strain collection UFZ für), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614 or they can be synthesized by known methods.
  • Mutations can be generated in the nucleic acid molecules used according to the invention by means of molecular biological techniques known per se, which makes it possible to synthesize further enzymes with analogous or similar properties which are likewise used in the method according to the invention. Mutations can be deletion mutations leading to truncated enzymes. By other molecular mechanisms, e.g. Insertions, duplications, transpositions, gene fusion, nucleotide exchange or also gene transfer between different microorganism strains can likewise be produced modified enzymes with similar or analogous properties.
  • nucleic acid molecules can be accomplished using the nucleic acid molecules or dividers thereof.
  • the molecules hybridizing with the nucleic acid molecules also include fragments, derivatives and allelic variants of the nucleic acid molecules described above which encode an enzyme useful in the invention. By fragments are meant parts of the nucleic acid molecules that are long enough to encode the described enzyme.
  • Derivative is understood as meaning sequences of these molecules which differ from the sequences of the above-described nucleic acid molecules at one or more positions, but have a high degree of homology to these sequences.
  • Homology means a sequence identity of at least 40%, in particular an identity of at least 60%, preferably over 80% and more preferably over 90%, 95%, 97% or 99% at the nucleic acid level.
  • the encoded enzymes have a sequence identity to the indicated amino acid sequences of at least 60%, preferably of at least 80%, more preferably of at least 95%, most preferably at least 99% at the amino acid level.
  • the deviations can be caused by deletion, substitution, insertion or recombination. These may be naturally occurring variations, for example sequences from other organisms, or mutations, which mutations may occur naturally or by directed mutagenesis (UV rays, X-rays, chemical agents or others). Furthermore, the variants may be synthetically produced sequences.
  • variants have certain common characteristics, such as enzyme activity, active enzyme concentration, subunits; functional groups, immunological reactivity, conformation and / or physical properties, such as gel electrophoresis run, chromatographic behavior, solubility, sedimentation coefficients, pH optimum, temperature optimum, spectroscopic properties, stability and / or others.
  • the invention further relates to the novel proteins with the sequence Nos. 2 and 4 and a heterodimeric protein comprising the Seq. No. 2 and Seq. No. 4 as well as the protein with the sequence no. 4 to at least 99% homologs.
  • SEQ ID NO: 1 shows the 1644 bp nucleotide sequence for the large subunit of the cobalamin-dependent mutase from DSM 18028.
  • SEQ ID NO: 2 shows the amino acid sequence of the large subunit of the cobalamin-dependent mutase from DSM 18028 comprising 548 aa.
  • SEQ ID NO: 3 shows 369 bp of partial nucleotide sequence for the small subunit of the cobalamin-dependent mutase from DSM 18028.
  • SEQ ID NO: 4 shows the partial sequence of the subunit of the cobalamin-dependent mutase from DSM 18028 comprising 123 AA.
  • SEQ ID NO: 5 and 6 show the amino acid sequences comprising 562 and 135 AA, respectively, of a cobalamin-dependent mutase from Xanthobacter autotrophicus Py2.
  • SEQ ID NO: 7 and 8 show the 1689 and 408 bp of the nucleotide sequence for the cobalamin-dependent mutases from Xanthobacter autotrophicus Py2.
  • SEQ ID NOs: 9 and 10 show the 563 and 135 AA, respectively, amino acid sequences of a cobalamin-dependent mutase from Rhodobacter sphaeroides ATCC 17029.
  • SEQ ID NOs: 11 and 12 show the 1692 and 408 bp, respectively, of the nucleotide sequence for the cobalamin-dependent mutases from Rhodobacter sphaeroides ATCC 17029.
  • SEQ ID NO: 13 and 14 show the 569 and 164 AS, respectively, amino acid sequences of a cobalamin-dependent mutase from Nocardoides sp. JS614.
  • SEQ ID NOS: 15 and 16 show the 1710 and 495 bp of the nucleotide sequence for the cobalamin-dependent mutases from Nocardoides sp. JS614.
  • the 2-hydroxy-2-methylcarboxylic acids prepared according to the invention can be isolated by treatment of the culture medium (after removal of undissolved constituents such as microbial cells) by methods already known. Such methods are in addition to other z. As concentration, ion exchange, distillation, electrodialysis, extraction and crystallization. The product can be isolated as a salt or (after acidification) as a protonated 2-hydroxy-2-methylcarboxylic acid.
  • 2-Hydroxy-2-methylcarboxylic acids can be dehydrated by a variety of methods to the corresponding unsaturated 2-methylcarboxylic acids.
  • the produced 2-hydroxy-2-methylcarboxylic acid are dehydrated according to the known processes of the prior art.
  • the dehydration of the 2-hydroxy-2-methylcarboxylic acids can be carried out by using metal oxides, metal hydroxides, ion exchange resins, alumina, silica, amines, phosphines, alkali metal alkoxides and carboxylates.
  • Typical reaction temperatures are between 160 ° C and 250 ° C.
  • the Preparation of methacrylic acid by dehydration of 2-hydroxyisobutyric acid in the presence of NaOH at temperatures of about 185 ° C.
  • the methacrylic acid and its homologs produced by this process find useful application in a whole range of industries, e.g. B. as additives and in coatings.
  • the method combines in contrast to the previously known methods, the desired benefits of a low-temperature process, the use of environmentally harmful starting materials and low waste generation.
  • Microbial cells from strain HCM-10 (DSM 18028) characterized by a 3-hydroxycarbonyl-CoA ester producing and 3-hydroxycarbonyl-CoA ester isomerizing activity or the isolated protein subunits with sequence no. 2 and no. 4 ,
  • the microbial strain used for the preparation of 2-hydroxy-2-methylcarboxylic acids was isolated as described below. Stock cultures are stored in 20% glycerol solution in liquid nitrogen.
  • Strain HCM-10 was enriched from groundwater on a basal medium (Table 1) with tert-butyl alcohol as the sole source of carbon and energy. Phylogenetically, the strain belongs to the Rubrivivax-leptothrix group. ⁇ b> Table 1 ⁇ / b> Basal medium (mg / L) NH 4 C1 761.4 biotin 0.02 KH 2 PO 4 340.25 folic acid 0.02 K 2 HPO 4 435.45 Pyridoxine HCl 0.1 CaCl 2 ⁇ 6 H 2 O 5.47 Thiamine HCl 0.05 MgSO 4 ⁇ 7H 2 O 71.2 riboflavin 0.05 ZnSO 4 ⁇ 7H 2 O 0.44 nicotinic acid 0.05 MnSO 4 ⁇ H 2 O 0.615 DL-Ca pantothenate 0.05 CuSO 4 ⁇ 5 H 2 O 0,785 p-aminobenzoic acid 0.05 CoCl 2 ⁇ 6 H 2 O 0.2 lipoic
  • Cells were used immediately after harvest. Intact cells can without further pretreatment, such. B. permeabilization, are used. In addition, the cells may be used permeabilized (eg, by treatment with toluene, detergents, or by freeze-thaw cycles) to enhance the diffusion rates of substances into and out of the cells.
  • the concentration of 2-hydroxyisobutyric acid and 3-hydroxybutyric acid in the culture liquid or in the reaction mixture were by gas chromatography acid methanolysis using a FFAP column and a FID detector.
  • a suspension of 1 g (dry weight) cells of strain HCM-10 in 100 mL basal medium was filled in 120 mL serum bottles.
  • 50 mg of 3-hydroxybutyric acid were added and the suspension was incubated on a rotating shaker at 30 ° C. After 0.3 h aerobic incubation, the suspension was gassed with nitrogen and incubated for a further 4.4 h at 30 ° C with shaking.
  • Samples were taken at various times and the content of 2-hydroxyisobutyric acid and 3-hydroxybutyric acid in the cell-free supernatant determined after centrifuging the suspension.
  • 2-hydroxyisobutyric acid was found to be the sole product released in the anaerobic phase. In the aerobic initial phase, however, 3-hydroxybutyric acid was apparently completely degraded ( Fig. 1 ).
  • the yield of 2-hydroxyisobutyric acid in this case was 5.1%, about 80% of the 3-hydroxybutyric acid remained in the reaction liquid.
  • Cell-free crude extract of strain HCM-10 was prepared by disintegration of the cells in a ball mill, cell debris was subsequently separated by centrifugation.
  • Cell-free crude extract at a concentration of 10 mg protein in 5 mL 50 mM potassium phosphate buffer (containing 1 mM MgCl 2 at pH 7.2) was placed in 10 mL closable glass jars.
  • To this extract was further added 0.01 mM coenzyme B12, 1 mM coenzyme A, 1 mM ATP and 4.25 mg 3-hydroxybutyric acid.
  • the reaction liquid was gassed with nitrogen, the reaction vessel sealed and incubated with shaking at 30 ° C for 2 h.
  • the reaction products were analyzed as shown above.
  • the yield of 2-hydroxyisobutyric acid was 9% in this case, about 88% of the 3-hydroxybutyric acid remained in the reaction liquid ( Fig. 2 ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Enzymatic preparation of 2-hydroxy-2-methylcarboxylic acid from 3-hydroxycarboxylic acid, comprises producing 3-hydroxycarboxylic acid in an aqueous reaction solution containing 3-hydroxycarboxylic acid-CoA-mutase-activity exhibiting unit, which possesses both 3-hydroxycarbonyl CoA-ester producing- and 3-hydroxycarbonyl-CoA-ester isomerizing activity; incubating the reaction solution; and subsequently converting to 2-hydroxy-2-methylcarboxylic acid as an acid or in form of its salts. Independent claims are included for: (1) preparation of 2-3C-unsaturated isoalkenic acid using 2-hydroxy-2-methylcarboxylic acid dehydrate; (2) preparation of methyl acrylic acid using 2-hydroxyisobutyric acid dehydrate; (3) a microorganism strain HCM-10-DSM 18028; (4) a nucleic acid molecule coding enzyme with an activity of cobalamin-dependent mutase such as: nucleic acid molecule of protein code comprises fully defined 548 amino acid sequence (SEQ ID NO: 2) and/or fully defined 123 amino acid sequence (SEQ ID NO: 4), as given in the specification; a nucleic acid molecule comprising 1644 bp nucleotide sequence (SEQ ID NO: 1) and/or 369 bp nucleotide sequence (SEQ ID NO: 3), as given in the specification; nucleic acid molecule with the above mentioned amino acid sequence or nucleotide sequence that are hybridized; and a nucleic acid molecule, whose nucleotide sequence based on the degeneration of the genetic code of the sequence of the mentioned nucleotide sequence or the hybridized nucleotide- or amino acid -sequence; (5) a protein with the activity of a cobalamin-dependent mutase codes the mentioned nucleic acid molecule; and (6) protein as heterodimer enzyme comprising amino acids sequence of (SEQ ID NO: 2) and (SEQ ID No: 4), which are at least 60% homologous to the protein.

Description

Die vorliegende Erfindung betrifft ein Verfahren zur enzymatischen Herstellung von 2-Hydroxy-2-methylcarbonsäuren aus 3-Hydroxycarbonsäuren, wobei eine 3-Hydroxycarbonsäure in einer wässrigen Reaktionslösung produziert und/oder zu dieser Reaktionslösung gegeben und inkubiert wird. Die wässrige Reaktionslösung enthält eine 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität aufweisende Einheit, welche sowohl 3-Hydroxycarbonyl-CoA-Ester produzierende als auch 3-Hydroxycarbonyl-CoA-Ester isomerisierende Aktivität besitzt und die Umwandlung der 3-Hydroxycarbonsäure in die entsprechende 2-Hydroxy-2-methylcarbonsäure bewirkt, welche als Säure oder in Form ihrer Salze gewonnen wird. In einer bevorzugten Ausführungsform umfasst die 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität aufweisende Einheit eine isolierte cobalaminabhängige Mutase und ggf. ein 3-Hydroxycarbonyl-CoA-Ester produzierendes Enzym oder Enzymsystem oder ist ein sie enthaltender Mikroorganismus. Vorzugsweise betrifft die Erfindung einen biotechnologischen Prozess zur Produktion von 2-Hydroxy-2-methylcarbonsäuren, wobei Mikroorganismen, die die gewünschte Mutase-Aktivität besitzen, in einem wässrigen System mit Hilfe einfacher Naturstoffe kultiviert werden und intrazellulär entstehende 3-Hydroxycarbonyl-CoA-Ester zu den entsprechenden 2-Hydroxy-2-methylcarbonsäuren umgewandelt werden. Die Erfindung umfasst ebenfalls die Produktion von ungesättigten 2-Methylcarbonsäuren, wobei die gewonnenen 2-Hydroxy-2-methylcarbonsäuren durch Dehydratisierung in die korrespondierenden ungesättigten 2-Methylcarbonsäuren (Methacrylsäure und höhere Homologe) umgewandelt werden.The present invention relates to a process for the enzymatic preparation of 2-hydroxy-2-methylcarboxylic acids from 3-hydroxycarboxylic acids, wherein a 3-hydroxycarboxylic acid is produced in an aqueous reaction solution and / or added to this reaction solution and incubated. The aqueous reaction solution contains a 3-hydroxycarboxylic acid CoA mutase activity unit having both 3-hydroxycarbonyl-CoA ester producing and 3-hydroxycarbonyl-CoA ester isomerizing activity and converting the 3-hydroxycarboxylic acid to the corresponding 2 -Hydroxy-2-methylcarboxylic acid, which is obtained as acid or in the form of its salts. In a preferred embodiment, the 3-hydroxycarboxylic acid CoA mutase activity-comprising moiety comprises an isolated cobalamin-dependent mutase and optionally a 3-hydroxycarbonyl-CoA ester-producing enzyme or enzyme system or is a microorganism containing it. Preferably, the invention relates to a biotechnological process for the production of 2-hydroxy-2-methylcarboxylic acids, wherein microorganisms having the desired mutase activity are cultured in an aqueous system with the aid of simple natural substances and intracellularly formed 3-hydroxycarbonyl-CoA esters the corresponding 2-hydroxy-2-methylcarboxylic acids are converted. The invention also includes the production of unsaturated 2-methylcarboxylic acids wherein the recovered 2-hydroxy-2-methylcarboxylic acids are converted by dehydration into the corresponding unsaturated 2-methylcarboxylic acids (methacrylic acid and higher homologs).

In einer bevorzugten Ausführung der Erfindung wird als 3-Hydroxycarbonyl-CoA-thioester produzierender und 3-Hydroxycarbonyl-CoA-thioester isomerisierender Mikroorganismus der Stamm HCM-10 (DSM 18028) eingesetzt.In a preferred embodiment of the invention, the strain HCM-10 (DSM 18028) is used as the 3-hydroxycarbonyl-CoA thioester-producing and 3-hydroxycarbonyl-CoA thioester isomerizing microorganism.

Methacrylsäure sowie homologe ungesättigte 2-Methylcarbonsäuren finden breite Anwendung bei der Produktion von Acrylglasscheiben, Spritzgussformprodukten, Beschichtungen und vielen anderen Produkten.Methacrylic acid as well as homologous unsaturated 2-methylcarboxylic acids are widely used in the production of acrylic sheets, injection molded products, coatings and many other products.

Mehrere Prozesse zur Herstellung von Methacrylsäure und deren Homologen sind bekannt. Allerdings basiert der weltweit größte Teil der kommerziellen Produktion auf einem Verfahren zur Hydrolyse der Amid-Sulfate von Methacrylsäure und deren Homologe, die aus den entsprechenden 2-Hydroxynitrilen produziert werden ( W. Bauer, "Methacrylic acid and derivatives", in: Ullmann's Encyclopedia of Industrial Chemistry, 5. Auflage, Herausgeber: B. Elvers, S. Hawkins, G. Schulz, VCH, New York, 1990, Bd. A16, S. 441-452 ; A. W. Gross, J. C. Dobson, "Methacrylic acid and derivatives", in Kirk-Othmer Encyclopedia of Chemical Technology, 4. Auflage, Herausgeber: J. 1. Kroschwitz, M. Howe-Grant, John Wiley & Sons, New York, 1995, Bd. 16, S. 474-506 ). Bei dieser Methode werden beispielsweise etwa 1,6 kg Schwefelsäure zur Produktion von 1 kg Methacrylsäure benötigt. Aus diesem Grunde wären alternative Verfahren für die kommerzielle Produktion von Methacrylsäure vorteilhaft, die ohne eine Wiedergewinnung der Schwefelsäure (und dem damit verbundenen hohen Energieaufwand) auskommt.Several processes for the production of methacrylic acid and its homologues are known. However, the world's largest part of commercial production is based on a process for the hydrolysis of the amide sulfates of methacrylic acid and its homologs, which are produced from the corresponding 2-hydroxynitriles ( W. Bauer, "Methacrylic Acid and Derivatives", in: Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed., Ed .: B. Elvers, S. Hawkins, G. Schulz, VCH, New York, 1990, Vol. A16, p. 441-452 ; AW Gross, JC Dobson, "Methacrylic Acid and Derivatives", in Kirk-Othmer Encyclopedia of Chemical Technology, 4th Ed., Editors: J. 1. Kroschwitz, M. Howe-Grant, John Wiley & Sons, New York, 1995, Vol. 16, p. 474-506 ). For example, this method requires about 1.6 kg of sulfuric acid to produce 1 kg of methacrylic acid. For this reason, alternative methods would be advantageous for the commercial production of methacrylic acid, which does not require the recovery of sulfuric acid (and the associated high energy expenditure).

Die chemische Umwandlung von 2-Hydroxyisobuttersäure in Methacrylsäure ist durch die Patente US 3,666,805 and US 5,225,594 bekannt gemacht worden. Hier wird 2-Hydroxyisobuttersäure durch Einsatz von Metalloxiden, Metallhydroxiden, lonenaustauscherharzen, Tonerde, Siliziumdioxid, Amine, Phosphine, Alkalimetallalkoxide und -carboxylate dehydratisiert. Übliche Reaktionstemperaturen liegen zwischen 160 °C und 250 °C. Mit diesem Verfahren konnten Methacrylsäure-Ausbeuten von bis zu 96 % erzielt werden.The chemical conversion of 2-hydroxyisobutyric acid into methacrylic acid is covered by the patents US 3,666,805 and US 5,225,594 been made known. Here, 2-hydroxyisobutyric acid is dehydrated by use of metal oxides, metal hydroxides, ion exchange resins, alumina, silica, amines, phosphines, alkali metal alkoxides and carboxylates. Typical reaction temperatures are between 160 ° C and 250 ° C. With this method, methacrylic acid yields of up to 96% could be achieved.

Ein alternatives Verfahren zur Produktion von Methacrylsäure und deren Homologe ergibt sich durch Hydrolyse von 2-Hydroxynitrilen zu den korrespondierenden 2-Hydroxy-2-methylcarbonsäuren unter Nutzung von Nitril-hydrolysierenden Enzymen. Dabei handelt es sich um Nitrilase oder eine Kombination aus Nitril-Hydratase und Amidase ( A. Banerjee, R. Sharma, U. C. Banerjee, 2002, "The nitrile-degrading enzymes: current status and future prospects", Appl. Microbiol. Biotechnol., 60:33-44 ). Dieses Verfahren ist durch mehrere Patente geschützt ( US 6,582,943 B1 ). Ein schwerwiegender Nachteil dieser Methode ist die Instabilität der Nitrile im für eine effiziente Nitril-hydrolisierende Enzymaktivität benötigten neutralen pH-Bereich. Der Zerfall der Nitrile im Reaktionsgemisch führt zu einer Akkumulation von Ketonen und Cyanid, die beide die Nitril-hydrolisierenden Enzymaktivitäten hemmen.An alternative method of producing methacrylic acid and its homologs is by hydrolysis of 2-hydroxynitriles to the corresponding 2-hydroxy-2-methylcarboxylic acids using nitrile-hydrolyzing enzymes. It is nitrilase or a combination of nitrile hydratase and amidase ( A. Banerjee, R. Sharma, UC Banerjee, 2002, "The nitrile-degrading enzymes: current status and future prospects", Appl. Microbiol. Biotechnol., 60: 33-44 ). This procedure is protected by several patents ( US Pat. No. 6,582,943 B1 ). A serious disadvantage of this method is the instability of the nitriles in the neutral pH range required for efficient nitrile hydrolyzing enzyme activity. Of the Decay of the nitriles in the reaction mixture leads to an accumulation of ketones and cyanide, both of which inhibit the nitrile-hydrolyzing enzyme activities.

Ein genereller Nachteil beider Verfahren, d.h. des zurzeit dominierenden Verfahrens auf Basis der Amid-Sulfate und des enzymatischen Nitril-hydrolysierenden Verfahrens, ist der Bedarf an 2-Hydroxynitriten. Diese müssen erst aus umweltschädlichen Edukten, namentlich Ketone und Cyanid, hergestellt werden.A general disadvantage of both methods, i. The currently dominant method based on the amide sulfates and the enzymatic nitrile hydrolyzing process, is the need for 2-Hydroxynitriten. These must first be produced from environmentally harmful educts, namely ketones and cyanide.

Deshalb wären Verfahren zur Produktion von Methacrylsäure und deren Homologe, die auf einfachen umweltunschädlichen Edukten basieren, von Vorteil.Therefore, processes for the production of methacrylic acid and its homologs, which are based on simple environmentally benign educts, would be advantageous.

Der Erfindung lag deshalb die Aufgabe zugrunde, nach alternativen Möglichkeiten zur Produktion von 2-Hydroxy-2-methylcarbonsäuren zu suchen und Mittel und Verfahren bereitzustellen, die möglichst auf der Anwendung einfacher, umweitunschädticher Edukte basieren, wenig Energie verbrauchen und wenig Abfallstoffe produzieren.The invention therefore an object of the invention to seek alternative ways to produce 2-hydroxy-2-methylcarboxylic acids and provide means and methods that are based on the application of simple, umunschunschädticher reactants as possible, consume little energy and produce little waste.

Die Aufgabe wird durch ein enzymatisches Verfahren zur Herstellung von 2-Hydroxy-2-methylcarbonsäuren aus 3-Hydroxycarbonsäuren gelöst. Erfindungsgemäß wird die 3-Hydroxycarbonsäure in einer wässrigen Reaktionslösung, welche eine 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität aufweisende Einheit besitzt, produziert und/oder zu einer solchen Reaktionslösung gegeben. Unter einer 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität aufweisenden Einheit versteht man im Sinne der Erfindung eine Einheit umfassend eine cobalaminabhängige Mutase und ggf. ein 3-Hydroxycarbonyl-CoA-Ester produzierendes Enzym oder Enzymsystem bzw. ein sie umfassendes oder produzierendes biologisches System, welche 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität besitzen und sowohl 3-Hydroxycarbonyl-CoA-Ester produzierende als auch 3-Hydroxycarbonyl-CoA-Ester isomerisierende Aktivität zeigen. Nach Inkubation wird anschließend die entsprechend umgewandelte 2-Hydroxy-2-methylcarbonsäure als Säure oder in Form ihrer Salze gewonnen.The object is achieved by an enzymatic process for the preparation of 2-hydroxy-2-methylcarboxylic acids from 3-hydroxycarboxylic acids. According to the invention, the 3-hydroxycarboxylic acid is produced in an aqueous reaction solution which has a 3-hydroxycarboxylic acid CoA mutase activity-containing unit, and / or added to such a reaction solution. For the purposes of the invention, a unit comprising a 3-hydroxycarboxylic acid CoA mutase activity is understood as meaning a unit comprising a cobalamin-dependent mutase and optionally a 3-hydroxycarbonyl-CoA ester-producing enzyme or enzyme system or a biological system comprising or producing the same. which have 3-hydroxycarboxylic acid CoA mutase activity and show both 3-hydroxycarbonyl-CoA ester producing and 3-hydroxycarbonyl-CoA ester isomerizing activity. After incubation, the correspondingly converted 2-hydroxy-2-methylcarboxylic acid is then obtained as acid or in the form of its salts.

Vorzugsweise betrifft die Erfindung einen biotechnologischen Prozess zur Produktion von 2-Hydroxy-2-methylcarbonsäuren unter Verwendung von Mikroorganismen. Diese Mikroorganismen besitzen i.d.R. 3-Hydroxycarbonyl-CoA-Ester synthetisierende Aktivität und sind in der Lage, eine solche cobalaminabhängige Mutase zu produzieren bzw. umfassen eine solche Mutase und sind durch die 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität in der Lage, intrazellulär aus einfachen Naturstoffen (aus Edukten, wie z.B. Zucker und/oder Alkoholen und/oder organischen Säuren und deren Derivaten) gebildete 3-Hydroxycarbonyl-CoA-Ester in die korrespondierenden 2-Hydroxy-2-methylcarbonyl-CoA-Ester umzuwandeln.Preferably, the invention relates to a biotechnological process for the production of 2-hydroxy-2-methylcarboxylic acids using microorganisms. These microorganisms usually have 3-hydroxycarbonyl-CoA-esters synthesizing activity and are able to produce such a cobalamin-dependent mutase or include such a mutase and are by the 3-hydroxycarboxylic acid-CoA mutase activity capable of intracellularly from simple natural products (starting materials, such as sugar and / or or alcohols and / or organic acids and their derivatives) converted 3-hydroxycarbonyl-CoA esters into the corresponding 2-hydroxy-2-methylcarbonyl-CoA ester.

Das erfindungsgemäße Verfahren ist insbesondere dadurch gekennzeichnet, dass man Mikroorganismen, die die cobalaminabhängige Mutase produzieren bzw. umfassen und 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität besitzen, in wässrigen Systemen zur Umwandlung von 3-Hydroxycarbonsäuren in die entsprechende 2-Hydroxy-2-methylcarbonsäure einsetzt.The process according to the invention is characterized in particular by the fact that microorganisms which produce the cobalamin-dependent mutase and have 3-hydroxycarboxylic acid-CoA mutase activity in aqueous systems for the conversion of 3-hydroxycarboxylic acids into the corresponding 2-hydroxy-2-one methylcarboxylic acid is used.

In einer bevorzugten Verfahrensvariante werden Mikroorganismen, die 3-Hydroxycarbonsäure-CoA-Mutase-Aktivität umfassen und sowohl 3-Hydroxycarbonyl-CoA-Thioester produzierende als auch 3-Hydroxycarbonyl-CoA-Thioester isomerisierende Aktivität besitzen in einem wässrigen System mit nachwachsenden Rohstoffen oder aus der Verwertung nachwachsender Rohstoffe anfallender Abfallprodukte als Kohlenstoff- und Energiequelle kultiviert. Dabei werden die intrazellulär gebildeten 3-Hydroxycarbonsäure-CoA-Thioester zu den korrespondierenden 2-Hydroxy-2-methylcarbonsäuren umgewandelt. Vorzugsweise erfolgt die Reaktion unter Zugabe externer 3-Hydroxycarbonsäure. Anschließend wird die entsprechende 2-Hydroxy-2-methylcarbonsäure als Säure oder in Form ihrer Salze soliert.In a preferred process variant, microorganisms comprising 3-hydroxycarboxylic acid CoA mutase activity and having both 3-hydroxycarbonyl-CoA thioester producing and 3-hydroxycarbonyl-CoA thioester isomerizing activity in an aqueous system with renewable resources or from Utilization of renewable raw materials resulting waste products as carbon and energy source cultivated. The intracellularly formed 3-hydroxycarboxylic acid CoA thioesters are converted to the corresponding 2-hydroxy-2-methylcarboxylic acids. Preferably, the reaction takes place with the addition of external 3-hydroxycarboxylic acid. Subsequently, the corresponding 2-hydroxy-2-methylcarboxylic acid is solubilized as acid or in the form of its salts.

Dieses neuartige biotechnologische Verfahren, das die Produktion von 3-Hydroxycarbonsäuren aus einfachen Naturstoffen und deren Isomerisierung zu 2-Hydroxy-2-methylcarbonsäuren nutzt, ist in der Lage das oben genannte Problem zu lösen.This novel biotechnological process, which utilizes the production of 3-hydroxycarboxylic acids from simple natural products and their isomerization to 2-hydroxy-2-methylcarboxylic acids, is capable of solving the above-mentioned problem.

In einer bevorzugten Ausführung der Erfindung umfasst das Verfahren die folgenden Schritte

  1. (a) in einem geeigneten biologischen System, das 3-Hydroxycarbonyl-CoA-Ester synthetisierende Aktivität und Mutase-Aktivität besitzt, erfolgt die Produktion von 3-Hydroxycarbonsäuren aus einfachen Naturstoffen und die anschließende Umwandlung in 2-Hydroxy-2-methylcarbonsäuren und
  2. (b) Isolierung der 2-Hydroxy-2-methylcarbonsäuren als freie Säuren oder als deren korrespondierende Salze.
In a preferred embodiment of the invention, the method comprises the following steps
  1. (a) in a suitable biological system having 3-hydroxycarbonyl-CoA ester synthesizing activity and mutase activity, the production of 3-hydroxycarboxylic acids from simple natural products and the subsequent conversion into 2-hydroxy-2-methylcarboxylic acids and
  2. (b) isolating the 2-hydroxy-2-methylcarboxylic acids as free acids or as their corresponding salts.

Die so gewonnenen 2-Hydroxy-2-methylcarbonsäuren können vorteilhaft zur Herstellung von C2-C3-ungesättigten Isoalkensäuren (Methacrylsäure und deren Homologe) eingesetzt werden, was durch Dehydratisierung der in (a) und (b) hergestellten Säuren oder deren korrespondierenden Salzen erfolgen kann. Diese Reaktionen sind im Folgenden dargestellt:

  • einfache Naturstoffe (z. B. nachwachsende Rohstoffe oder aus der Verwertung nachwachsender Rohstoffe anfallende Abfallprodukte, wie z.B. Zucker, organische Säuren oder Alkohole) → 3-Hydroxycarbonsäuren → 2-Hydroxy-2-methylcarbonsäuren (z. B. durch Stamm HCM-10)
  • 2-Hydroxy-2-methylcarbonsäuren → Methacrylsäure und Homologe (z.B. in Gegenwart von NaOH und einer Temperatur von 185°C)
The 2-hydroxy-2-methylcarboxylic acids obtained in this way can advantageously be used for the preparation of C 2 -C 3 -unsaturated isoalkenoic acids (methacrylic acid and its homologs), which can be effected by dehydration of the acids or their corresponding salts prepared in (a) and (b) , These reactions are shown below:
  • simple natural substances (eg renewable raw materials or waste products resulting from the utilization of renewable raw materials, such as sugars, organic acids or alcohols) → 3-hydroxycarboxylic acids → 2-hydroxy-2-methylcarboxylic acids (eg by strain HCM-10)
  • 2-hydroxy-2-methylcarboxylic acids → methacrylic acid and homologs (eg in the presence of NaOH and a temperature of 185 ° C)

Die Reaktionsbedingungen (pH-Wert, lonenkonzentration, Sauerstoff/ Kohlendioxidbedarf, Spurenelemente, Temperaturen und ähnliches) werden dabei selbstverständlich so gewählt, dass die Mikroorganismen zu einer optimalen Umsetzung von 3-Hydroxycarbonsäuren zu 2-Hydroxy-2-methylcarbonsäuren befähigt sind. Unter diesen Verfahrensbedingungen kann die cobalaminabhängige Mutase im natürlichen Mikro-Milieu, also innerhalb der Zelle, eine höhere Stabilität und Effektivität aufweisen als das isolierte Enzym. Darüber hinaus kann unter geeigneten Bedingungen eine Zellvermehrung und somit eine Erhöhung der Mutase-Konzentration möglich sein. Somit bedeutet die enzymatische Umsetzung mittels Mikroorganismen ggf. einen bedeutenden Vorteil, was Zuverlässigkeit, Automatisierung und Einfachheit sowie Qualität und Ausbeute des Endproduktes des Verfahrens angeht.The reaction conditions (pH, ion concentration, oxygen / carbon dioxide requirement, trace elements, temperatures and the like) are of course chosen so that the microorganisms are capable of optimal conversion of 3-hydroxycarboxylic acids to 2-hydroxy-2-methylcarboxylic acids. Under these process conditions, the cobalamin-dependent mutase in the natural micro-environment, ie within the cell, a higher stability and effectiveness than the isolated enzyme. In addition, cell proliferation and thus an increase in mutase concentration may be possible under suitable conditions. Thus, the enzymatic conversion by means of microorganisms may be a significant advantage in terms of reliability, automation and simplicity as well as quality and yield of the final product of the process.

Für die erfindungsgemäße enzymatische Umsetzung von 3-Hydroxycarbonsäuren in 2-Hydroxy-2-methylcarbonsäuren ist es auch möglich, die.3-Hydroxycarbonsäure-CoA-Mutase-Aktivität besitzende Einheit, also eine cobalaminabhängige Mutase vorzugsweise in Kombination mit einer CoA-Ester synthetisierenden Aktivität, in gereinigter, angereicherter und/oder isolierter Form in die Reaktionslösung einzubringen, wobei die Enzyme z.B. natürlichen Ursprungs sein können. Selbstverständlich können die Enzyme rekombinant hergestellte Enzyme aus einem gentechnisch veränderten Organismus sein.For the inventive enzymatic reaction of 3-hydroxycarboxylic acids in 2-hydroxy-2-methylcarboxylic acids, it is also possible to use the 3-hydroxycarboxylic acid CoA mutase activity possessing unit, so a cobalamin-dependent mutase, preferably in combination with a CoA ester synthesizing activity, in purified, enriched and / or isolated form in the reaction solution, wherein the enzymes may be of natural origin, for example. Of course, the enzymes may be recombinantly produced enzymes from a genetically engineered organism.

Die Enzyme werden im erfindungsgemäßen Verfahren im Sinne der Erfindung als Katalysatoren sowohl in Form von intakten mikrobiellen Zellen als auch in Form von permeabilisierten mikrobiellen Zellen eingesetzt. Weitere Einsatzmöglichkeiten bestehen in Form von Komponenten (eine oder mehrere) aus mikrobiellen Zellextrakten, aber auch in partiell gereinigter oder gereinigter Form. Gegebenenfalls werden weitere CoA-Ester synthetisierende Enzyme, z.B. CoA-Transferase oder CoA-Synthetasen, erfindungsgemäß eingesetzt. Die enzymatischen Katalysatoren können immobilisiert sein oder an ein gelöstes oder ungelöstes Trägermaterial angeheftet sein.The enzymes are used in the novel process according to the invention as catalysts both in the form of intact microbial cells and in the form of permeabilized microbial cells. Other uses exist in the form of components (one or more) of microbial cell extracts, but also in partially purified or purified form. Optionally, other CoA ester synthesizing enzymes, e.g. CoA transferase or CoA synthetases, used according to the invention. The enzymatic catalysts may be immobilized or attached to a dissolved or undissolved carrier material.

In einer bevorzugten Ausführungsvariante werden bestimmte Zellkompartimente oder Teile davon voneinander getrennt oder vereinigt, das heißt, Kohlenhydratstrukturen, Lipide oder Proteine und/oder Peptide sowie Nukleinsäuren, die in der Lage sind, die Mutase-Aktivität aufweisende Einheit positiv oder negativ zu beeinflussen, können kombiniert oder getrennt werden. Um eine solche Beeinflussung bewusst zu nutzen, werden aus den Mikroorganismen z.B. fachgemäß Rohextrakte hergestellt, welche ggf. zentrifugiert werden um eine erfindungsgemäße Umsetzung mit dem Sediment oder dem Überstand durchführen zu können.In a preferred embodiment, certain cell compartments or portions thereof are separated or pooled, that is, carbohydrate structures, lipids or proteins and / or peptides, as well as nucleic acids capable of positively or negatively affecting unit having mutase activity can be combined or be separated. In order to consciously use such an influence, the microorganisms, e.g. prepared crude extracts, which are optionally centrifuged in order to carry out an inventive reaction with the sediment or the supernatant can.

3-Hydroxycarbonsäuren (wie z. B. 3-Hydroxybuttersäure) oder genauer gesagt deren intrazellulärer CoA-Thioester 3-Hydroxycarbonyl-CoA können leicht durch eine große Zahl von Bakterienstämmen aus einfachen Naturstoffen hergestellt werden. Diese Säuren stellen die Grundbausteine/Monomere für den weit verbreiteten bakteriellen Kohlenstoff- und Energiespeicherstoff Poly-3-hydroxyalkanoat dar. Umlagerungen des Kohlenstoffs innerhalb des Skelettes von Carbonsäuren sind in bakteriellen als auch in anderen biologischen Systemen ebenfalls weit verbreitet. Bisher konnte allerdings kein biologisches System zur Umwandlung von 3-Hydroxycarbonyl-CoA-Ester in die korrespondierenden 2-Hydroxy-2-methylcarbonyl-CoA-Ester nachgewiesen werden. Die Erfindung beruht auf der überraschenden Erkenntnis, dass Systeme mit cobalaminabhängiger Mutase-Aktivität beide Eigenschaften besitzen.3-hydroxycarboxylic acids (such as 3-hydroxybutyric acid) or, more specifically, their intracellular CoA thioesters 3-hydroxycarbonyl-CoA can be readily prepared by a large number of bacterial strains from simple natural products. These acids are the building blocks / monomers for the widely-used bacterial carbon and energy storage material poly-3-hydroxyalkanoate. Rearrangements of carbon within the skeleton of carboxylic acids are also widely used in bacterial as well as other biological systems. So far, however, no biological system for the conversion of 3-hydroxycarbonyl-CoA ester be detected in the corresponding 2-hydroxy-2-methylcarbonyl-CoA esters. The invention is based on the surprising discovery that systems with cobalamin-dependent mutase activity have both properties.

Cobalaminabhängige Mutasen enthaltende Mikroorganismen sind z.B. Methylibium petroleiphilum PM1, Methylibium sp. R8 (Stammsammlung UFZ Leipzig), der βproteobakterielle Stamm HCM-10, Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) oder Nocardioides sp. JS614.Cobalamin-dependent mutases containing microorganisms are, for example, methylibium petroleiphilum PM1, methylibium sp. R8 (strain collection UFZ Leipzig), the βproteobacterial strain HCM-10, Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614.

Ein bevorzugt geeignetes biologisches System wurde mit dem Stamm HCM-10 gefunden. Er wurde gemäß Budapester Vertrag über die Hinterlegung von Mikroorganismen für die Zwecke von Patentverfahren bei der Deutschen Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, DE unter der Nr. DSM 18028 am 13.03.2006 hinterlegt.A preferred suitable biological system was found with strain HCM-10. It was deposited under the Budapest Treaty on the deposit of microorganisms for the purposes of patent procedures at the German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, DE under the number DSM 18028 on 13.03.2006.

Unter Verwendung dieses bevorzugten biologischen Systems konnte eine besonders gute Ausbeute an 2-Hydroxy-2-methylcarbonsäuren, insbesondere von 2-Hydroxyisobuttersäure, erzielt werden. Jedoch ist die enzymatische Umsetzung durch Mikroorganismen keinesfalls auf diesen Stamm beschränkt. Sämtliche Organismen, die in der Lage sind, 3-Hydroxycarbonsäuren zu 2-Hydroxy-2-methylcarbonsäuren umzuwandeln, können erfindungsgemäß eingesetzt werden.Using this preferred biological system, a particularly good yield of 2-hydroxy-2-methylcarboxylic acids, in particular of 2-hydroxyisobutyric acid, could be achieved. However, enzymatic conversion by microorganisms is by no means limited to this strain. All organisms which are capable of converting 3-hydroxycarboxylic acids to 2-hydroxy-2-methylcarboxylic acids can be used according to the invention.

Dabei kann es sich um Mikroorganismen handeln, die zum einen über das gleiche Gen bzw. Genprodukt verfügen oder zum anderen ein analoges Gen besitzen, welches zu Genprodukten mit ähnlicher oder analoger Aktivität führt. D.h. 3-Hydroxycarbonyl-CoA-Mutase-Aktivitäten anderer Herkunft sind durch die Erfindung ebenfalls abgedeckt. Ebenso schließt die Erfindung transformierte Systeme, die eine oder eine ähnliche 3-Hydroxycarbonyl-CoA-Mutase-Aktivität wie Stamm HCM-10 oder die anderer Herkunft besitzen, mit ein.
Dazu können Mutanten, gentechnisch geänderte sowie isolierte Abwandlungen der Mikroorganismen zählen, z.B. Organismen, die aufgrund des Einführens einer Mutase-codierenden Nukleotidsequenz die gewünschte cobalaminabhängige Mutase-Aktivität aufweisen.
These may be microorganisms which on the one hand have the same gene or gene product or on the other hand have an analogous gene which leads to gene products with similar or analogous activity. That is, 3-hydroxycarbonyl-CoA mutase activities of other origin are also covered by the invention. Likewise, the invention includes transformed systems having a or a similar 3-hydroxycarbonyl-CoA mutase activity, such as strain HCM-10 or those of other origin.
These may include mutants, genetically modified as well as isolated modifications of the microorganisms, eg organisms that have the desired cobalamin-dependent mutase activity due to the introduction of a mutase-encoding nucleotide sequence.

Das bevorzugt eingesetzte biologische System (Stamm HCM-10 - DSM 18028) stellt 3-Hydroxycarbonyl-CoA-Ester als Thioester, aus einfachen Naturstoffen wie Zucker und/oder organischen Säuren und/oder Alkoholen und deren Derivaten her. Im hier verwendeten bevorzugten System werden die 3-Hydroxycarbonyl-CoA-Ester durch die cobalaminabhängige Kohlenstoffskelett-umgestaltende Mutase in 2-Hydroxy-2-methylcarbonyl-CoA-Ester umgewandelt, wie in Gleichung 1 beispielhaft für den Fall des (R)-3-Hydroxybutyryl-CoA gezeigt ist. Der CoA-Thioester wird im System hydrolysiert und die Säure ins Kulturmedium ausgeschieden.

Figure imgb0001
The preferred biological system used (strain HCM-10 - DSM 18028) produces 3-hydroxycarbonyl-CoA esters as thioesters, from simple natural products such as sugars and / or organic acids and / or alcohols and derivatives thereof. In the preferred system used herein, the 3-hydroxycarbonyl-CoA esters are converted to 2-hydroxy-2-methylcarbonyl-CoA ester by the cobalamin-dependent carbon skeleton transforming mutase, as exemplified in Equation 1 for the case of the ( R ) -3- Hydroxybutyryl-CoA is shown. The CoA thioester is hydrolyzed in the system and the acid is eliminated in the culture medium.
Figure imgb0001

Für das erfindungsgemäße Verfahren werden als bevorzugte Enzym-Katalysatoren die cobalaminabhängige Mutasen enthaltenden Mikroorganismenstämme HCM-10 (DSM 18028), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) oder Nocardioides sp. JS614, ihre Rohextrakte oder Teile eingesetzt. Die erfindungsgemäß verwendeten Stämme produzieren bevorzugt die Proteine mit den Sequenzen SEQ ID NO: 2 und/oder SEQ ID NO: 4 bzw. umfassen die Nukleinsäuresequenzen SEQ ID NO: 1 und/oder SEQ ID NO: 3 (HCM-10), die Proteine mit den Sequenzen SEQ ID NO: 5 und/oder SEQ ID NO: 6 bzw. umfassen die Nukleinsäuresequenzen SEQ ID NO: 7 und/oder SEQ ID NO: 8 (Xanthobacter autotrophicus Py2), die Proteine mit den Sequenzen SEQ ID NO: 9 und/oder SEQ ID NO: 10 bzw. umfassen die Nukleinsäuresequenzen SEQ ID NO: 11 und/oder SEQ ID NO: 12 (Rhodobacter sphaeroides ATCC 17029) oder die Proteine mit den Sequenzen SEQ ID NO: 13 und/oder SEQ ID NO: 14 bzw. umfassen die Nukleinsäuresequenzen SEQ ID NO: 15 und/oder SEQ ID NO: 16 (Nocardioides sp. JS614). Im Sinne der Erfindung können die genannten Proteine auch in angereicherter, isolierter oder synthetisch hergestellter Form eingesetzt werden.The preferred enzyme catalysts for the process according to the invention are the cobalamin-dependent mutase-containing microorganism strains HCM-10 (DSM 18028), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614, their crude extracts or parts used. The strains used according to the invention preferably produce the proteins having the sequences SEQ ID NO: 2 and / or SEQ ID NO: 4 or the nucleic acid sequences SEQ ID NO: 1 and / or SEQ ID NO: 3 (HCM-10) comprising the proteins with the sequences SEQ ID NO: 5 and / or SEQ ID NO: 6 or comprise the nucleic acid sequences SEQ ID NO: 7 and / or SEQ ID NO: 8 (Xanthobacter autotrophicus Py2), the proteins having the sequences SEQ ID NO: 9 and / or SEQ ID NO: 10 or comprise the nucleic acid sequences SEQ ID NO: 11 and / or SEQ ID NO: 12 (Rhodobacter sphaeroides ATCC 17029) or the proteins having the sequences SEQ ID NO: 13 and / or SEQ ID NO: 14 or comprise the nucleic acid sequences SEQ ID NO: 15 and / or SEQ ID NO: 16 (Nocardioides sp., JS614). For the purposes of the invention, the said proteins can also be used in enriched, isolated or synthetically produced form.

In einer weiteren bevorzugten Ausführungsvariante der Erfindung werden die Enzym-Katalysatoren, insbesondere Mikroorganismen, Rohextrakte, Teile davon und/oder die angereicherten oder isolierten Enzyme immobilisiert eingesetzt. Durch die Immobilisierung werden Enzyme, Zellorganellen und Zellen in einen unlöslichen und reaktionsraumbegrenzten Zustand versetzt. So können sie z.B. in einer Polymer-Matrix immobilisiert werden (z. B. Alginat-, Polyvinylalkohol- oder Polyacrylamid-Gele). Eine Immobilisierung kann auch auf gelösten oder ungelösten Trägermaterialien (z. B. Celit) zur Erleichterung der Katalysator-Wiedergewinnung und -benutzung erfolgen. Methoden zur Zell-Immobilisierung in einer Polymer-Matrix oder auf einem gelösten oder ungelösten Träger sind dem Fachmann bekannt und bereits ausführlich beschrieben worden. Die Enzymaktivitäten können ebenfalls aus den mikrobiellen Zellen isoliert werden. Diese können dann direkt als Katalysator oder in einer Polymer-Matrix oder auf einem gelösten oder ungelösten Träger immobilisiert eingesetzt werden. Die dazu nötigen Methoden sind dem Fachmann bekannt und beschrieben z.B. in Methods in Biotechnology, Bd. 1: Immobilization of enzymes and cells, Herausgeber: G. F. Bickerstaff, Humana Press, Totowa, New Jersey, 1997 .In a further preferred embodiment of the invention, the enzyme catalysts, in particular microorganisms, crude extracts, parts thereof and / or the enriched or isolated enzymes are immobilized. Immobilization places enzymes, cell organelles and cells in an insoluble and reaction-space limited state. For example, they can be immobilized in a polymer matrix (eg alginate, polyvinyl alcohol or polyacrylamide gels). Immobilization may also be carried out on dissolved or undissolved carrier materials (eg celite) to facilitate catalyst recovery and use. Methods for cell immobilization in a polymer matrix or on a dissolved or undissolved carrier are known to the person skilled in the art and have already been described in detail. The enzyme activities can also be isolated from the microbial cells. These can then be used directly immobilized as a catalyst or in a polymer matrix or on a dissolved or undissolved carrier. The methods necessary for this are known to the person skilled in the art and described, for example, in US Pat Methods in Biotechnology, Vol. 1: Immobilization of enzymes and cells, publisher: GF Bickerstaff, Humana Press, Totowa, New Jersey, 1997 ,

Die Umwandlung von 3-Hydroxycarbonsäuren in 2-Hydroxy-2-methylcarbonsäuren erfolgt bevorzugt im Rahmen eines kontinuierlichen Verfahrens, welches in einem durchströmten Reaktor durchgeführt werden kann, in dem mikrobielles Wachstum und somit die Produktbildung stattfindet. Unter einem kontinuierlichen Verfahren kann jedoch auch jedes System wachsender Zellen und katalysierender Enzyme verstanden werden, dem einerseits Nährlösung zugeführt wird und aus dem andererseits Kulturlösung, einschließlich enzymatisch gebildeter 2-Hydroxy-2-methylcarbonsäure abgezogen wird. Erfindungsgemäß kann das Verfahren auch als semikontinuierliches oder Batch-Verfahren durchgeführt werden.The conversion of 3-hydroxycarboxylic acids into 2-hydroxy-2-methylcarboxylic acids is preferably carried out in the context of a continuous process which can be carried out in a reactor through which microbial growth and thus product formation take place. However, a continuous process can also be understood to mean any system of growing cells and catalyzing enzymes to which nutrient solution is added on the one hand and from which, on the other hand, culture solution, including enzymatically formed 2-hydroxy-2-methylcarboxylic acid, is withdrawn. According to the invention, the method can also be carried out as a semicontinuous or batch process.

Wie bereits ausgeführt wird die 3-Hydroxycarbonsäure, die der Ausgangstoff für die 2-Hydroxy-2-methylcarbonsäure ist, bevorzugt durch enzymatische Umwandlung von Kohlenhydraten und/oder organischen Säuren und/oder Alkoholen bzw. deren Derivaten hergestellt. Im Zusammenhang mit der Erfindung kommen neben der cobalaminabhängigen Mutase gegebenenfalls weiterhin CoA-Ester synthetisierende Enzyme zum Einsatz, welche im Mikroorganismus vorhanden sind oder zugegeben werden. Dabei erfolgt die Umwandlung von Kohlenwasserstoffen und/oder Kohlenhydraten und/oder organischen Säuren und/oder Alkoholen bzw. dessen Derivaten in die 3-Hydroxycarbonsäure und von der 3-Hydroxycarbonsäure in die 2-Hydroxy-2-methylcarbonsäure in einem einzigen Verfahrensschritt, d.h. die Umwandlung der Ausgangssubstrate bis hin zu der 3-Hydroxycarbonsäure und die enzymatischen Umwandlungsreaktionen der 3-Hydroxycarbonsäure in die korrespondierende 2-Hydroxy-2-methylcarbonsäure laufen gleichzeitig oder leicht zeitversetzt in ein und derselben Reaktionslösung ab.As already stated, the 3-hydroxycarboxylic acid, which is the starting material for the 2-hydroxy-2-methylcarboxylic acid, is preferably prepared by enzymatic conversion of carbohydrates and / or organic acids and / or alcohols or derivatives thereof. In connection with the invention, in addition to the cobalamin-dependent mutase, it is furthermore possible to use, if appropriate, CoA-ester-synthesizing enzymes which are present or added in the microorganism become. In this case, the conversion of hydrocarbons and / or carbohydrates and / or organic acids and / or alcohols or derivatives thereof in the 3-hydroxycarboxylic acid and of the 3-hydroxycarboxylic acid in the 2-hydroxy-2-methylcarboxylic acid in a single process step, ie Conversion of the starting substrates to the 3-hydroxycarboxylic acid and the enzymatic conversion reactions of the 3-hydroxycarboxylic acid into the corresponding 2-hydroxy-2-methylcarboxylic acid proceed simultaneously or slightly delayed in one and the same reaction solution.

In einer ganz besonderen Ausführung der Erfindung wird zur Kultivierung ein Substrat mit einem tert. Butylrest als Kohlenstoff- und Energiequelle eingesetzt, vorzugsweise dient tert. Butylalkohol als einzige Kohlenstoff- und Energiequelle in einem Basalmedium.In a very particular embodiment of the invention, a substrate with a tert is used for culturing. Butyl used as a carbon and energy source, preferably tert. Butyl alcohol as the sole carbon and energy source in a basal medium.

Das erfindungsgemäße Verfahren ist vorzugsweise zur Herstellung von 2-Hydroxy-2-methylpropansäure (2-Hydroxyisobuttersäure) einsetzbar. Die bevorzugte Herstellung von 2-Hydroxyisobuttersäure ist weiterhin dadurch gekennzeichnet, dass extern 3-Hydroxybuttersäure zugegeben wird.The process according to the invention can preferably be used for the preparation of 2-hydroxy-2-methylpropanoic acid (2-hydroxyisobutyric acid). The preferred preparation of 2-hydroxyisobutyric acid is further characterized in that externally 3-hydroxybutyric acid is added.

Das Verfahren kann aerob, vorzugsweise beim Einsatz ganzer Zellen, durchgeführt werden oder auch anaerob, z.B. unter Stickstoffbegasung, vorzugsweise wenn Extrakte oder gereinigte Enzyme verwendet werden.The process may be performed aerobically, preferably using whole cells, or anaerobically, e.g. under nitrogen, preferably when extracts or purified enzymes are used.

Die Erfindung betrifft auch Nukleinsäuremoleküle, codierend ein Enzym mit der Aktivität einer cobalaminabhängigen Mutase, ausgewählt aus der Gruppe bestehend aus

  1. a) Nukleinsäuremolekülen, die ein Protein codieren, das die unter Seq. Nr. 2 und/oder Seq. Nr. 4 angegebene Aminosäuresequenzen umfasst;
  2. b) Nukleinsäuremolekülen, die die unter Seq. Nr. 1 und/oder Seq. Nr. 3 dargestellte Nukleotidsequenz umfassen.
The invention also relates to nucleic acid molecules encoding an enzyme having the activity of a cobalamin-dependent mutase selected from the group consisting of
  1. a) Nucleic acid molecules encoding a protein corresponding to those described in Seq. No. 2 and / or Seq. No. 4 amino acid sequences;
  2. b) Nucleic acid molecules corresponding to those described under Seq. No. 1 and / or Seq. No. 3 nucleotide sequence.

Es hat sich gezeigt, dass ein erfindungsgemäßes Enzym bevorzugt ein heterodimeres Protein darstellt, welches die unter Seq. Nr. 2 und Seq. Nr. 4 beschriebenen Untereinheiten umfasst und so eine hervorragende Enzymaktivität besitzt.It has been found that an enzyme according to the invention is preferably a heterodimeric protein which contains the enzymes described under Seq. No. 2 and Seq. No. 4 and thus has excellent enzyme activity.

Ein Nukleinsäuremolekül kann ein DNA-Molekül, vorzugsweise cDNA oder genomische DNA und/oder ein RNA-Molekül sein. Sowohl Nukleinsäuren als auch Proteine können aus natürlichen Quellen isoliert werden, vorzugsweise aus DSM 18028, aber z.B. auch aus Methylibium petroleiphilum PM1, Methylibium sp. R8 (Stammsammlung UFZ Leipzig), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) oder Nocardioides sp. JS614 oder sie können nach bekannten Verfahren synthetisiert werden.A nucleic acid molecule may be a DNA molecule, preferably cDNA or genomic DNA and / or an RNA molecule. Both nucleic acids and proteins can be isolated from natural sources, preferably from DSM 18028, but also for example from Methylibium petroleiphilum PM1, Methylibium sp. R8 (strain collection UFZ Leipzig), Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614 or they can be synthesized by known methods.

In den erfindungsgemäß verwendeten Nukleinsäuremolekülen können mittels an sich bekannter molekularbiologischer Techniken Mutationen erzeugt werden, was ermöglicht, dass weitere Enzyme mit analogen oder ähnlichen Eigenschaften synthetisiert werden können, die ebenfalls im erfindungsgemäßen Verfahren verwendet werden. Mutationen können Deletionsmutationen sein, die zu verkürzten Enzymen führen. Durch andere molekulare Mechanismen wie z.B. Insertionen, Duplikationen, Transpositionen, Genfusion, Nukleotidaustausch oder auch Gentransfer zwischen verschiedenen Mikroorganismenstämmen können ebenfalls modifizierte Enzyme mit ähnlichen oder analogen Eigenschaften erzeugt werden.Mutations can be generated in the nucleic acid molecules used according to the invention by means of molecular biological techniques known per se, which makes it possible to synthesize further enzymes with analogous or similar properties which are likewise used in the method according to the invention. Mutations can be deletion mutations leading to truncated enzymes. By other molecular mechanisms, e.g. Insertions, duplications, transpositions, gene fusion, nucleotide exchange or also gene transfer between different microorganism strains can likewise be produced modified enzymes with similar or analogous properties.

Die Identifizierung und Isolierung derartiger Nukleinsäuremoleküle kann unter Verwendung der Nukleinsäuremoleküle oder Teilern davon erfolgen. Die mit den Nukleinsäuremolekülen hybridisierenden Moleküle umfassen auch Fragmente, Derivate und allelische Varianten der oben beschriebenen Nukleinsäuremoleküle, die ein erfindungsgemäß verwendbares Enzym codieren. Unter Fragmente werden dabei Teile der Nukleinsäuremoleküle verstanden, die lang genug sind, um das beschriebene Enzym zu codieren. Unter Derivat werden Sequenzen dieser Moleküle verstanden, die sich von den Sequenzen der oben beschriebenen Nukleinsäuremoleküle an einer oder mehreren Positionen unterscheiden, aber einen hohen Grad an Homologie zu diesen Sequenzen aufweisen. Homologie bedeutet dabei eine Sequenzidentität von mindestens 40%, insbesondere eine Identität von mindestens 60%, vorzugsweise über 80% und besonders bevorzugt über 90%, 95%, 97% oder 99% auf Nukleinsäureebene. Dabei weisen die codierten Enzyme eine Sequenzidentität zu den angegebenen Aminosäuresequenzen von mindestens 60%, vorzugsweise von mindestens 80%, besonders bevorzugt von mindestens 95%, ganz besonders bevorzugt mindestens 99% auf Aminosäureebene auf. Die Abweichungen können dabei durch Deletion, Substitution, Insertion oder Rekombination entstanden sein. Es kann sich dabei um natürlich auftretende Variationen handeln, beispielsweise um Sequenzen aus anderen Organismen, oder um Mutationen, wobei diese Mutationen auf natürliche Weise auftreten können oder durch gezielte Mutagenese (UV-Strahlen, Röntgenstrahlen, chemische Mittel oder weitere). Ferner kann es sich bei den Varianten um synthetisch hergestellte Sequenzen handeln. Diese Varianten weisen bestimmte gemeinsame Charakteristika auf, wie z.B. Enzymaktivität, aktive Enzymkonzentration, Untereinheiten; funktionelle Gruppen, immunologische Reaktivität, Konformation und/oder physikalische Eigenschaften, wie das Laufverhalten in Gelelektrophorese, chromatographisches Verhalten, Löslichkeit, Sedimentationskoeffizienten, pH-Wert-Optimum, Temperatur-Optimum, spektroskopische Eigenschaften, Stabilität und/oder andere.The identification and isolation of such nucleic acid molecules can be accomplished using the nucleic acid molecules or dividers thereof. The molecules hybridizing with the nucleic acid molecules also include fragments, derivatives and allelic variants of the nucleic acid molecules described above which encode an enzyme useful in the invention. By fragments are meant parts of the nucleic acid molecules that are long enough to encode the described enzyme. Derivative is understood as meaning sequences of these molecules which differ from the sequences of the above-described nucleic acid molecules at one or more positions, but have a high degree of homology to these sequences. Homology means a sequence identity of at least 40%, in particular an identity of at least 60%, preferably over 80% and more preferably over 90%, 95%, 97% or 99% at the nucleic acid level. The encoded enzymes have a sequence identity to the indicated amino acid sequences of at least 60%, preferably of at least 80%, more preferably of at least 95%, most preferably at least 99% at the amino acid level. The deviations can be caused by deletion, substitution, insertion or recombination. These may be naturally occurring variations, for example sequences from other organisms, or mutations, which mutations may occur naturally or by directed mutagenesis (UV rays, X-rays, chemical agents or others). Furthermore, the variants may be synthetically produced sequences. These variants have certain common characteristics, such as enzyme activity, active enzyme concentration, subunits; functional groups, immunological reactivity, conformation and / or physical properties, such as gel electrophoresis run, chromatographic behavior, solubility, sedimentation coefficients, pH optimum, temperature optimum, spectroscopic properties, stability and / or others.

Gegenstand der Erfindung sind weiterhin auch die neuen Proteine mit der Sequenz Nr. 2 und 4 sowie ein heterodimeres Protein umfassend die Seq. Nr. 2 und Seq. Nr. 4 sowie die zum Protein mit der Sequenz Nr. 4 zu mindestens 99% Homologen.The invention further relates to the novel proteins with the sequence Nos. 2 and 4 and a heterodimeric protein comprising the Seq. No. 2 and Seq. No. 4 as well as the protein with the sequence no. 4 to at least 99% homologs.

SEQ ID NO: 1 zeigt die 1644 bp umfassende Nukleotidsequenz für die große Untereinheit der cobalaminabhängigen Mutase aus DSM 18028.
SEQ ID NO: 2 zeigt die 548 AS umfassende Aminosäuresequenz der großen Untereinheit der cobalaminabhängigen Mutase aus DSM 18028.
SEQ ID NO: 3 zeigt 369 bp der partiellen Nukleotidsequenz für die kleine Untereinheit der cobalaminabhängigen Mutase aus DSM 18028.
SEQ ID NO: 4 zeigt die 123 AS umfassende partielle Sequenz der Untereinheit der cobalaminabhängigen Mutase aus DSM 18028.
SEQ ID NO: 1 shows the 1644 bp nucleotide sequence for the large subunit of the cobalamin-dependent mutase from DSM 18028.
SEQ ID NO: 2 shows the amino acid sequence of the large subunit of the cobalamin-dependent mutase from DSM 18028 comprising 548 aa.
SEQ ID NO: 3 shows 369 bp of partial nucleotide sequence for the small subunit of the cobalamin-dependent mutase from DSM 18028.
SEQ ID NO: 4 shows the partial sequence of the subunit of the cobalamin-dependent mutase from DSM 18028 comprising 123 AA.

SEQ ID NO: 5 und 6 zeigen die 562 bzw. 135 AS umfassenden Aminosäuresequenzen einer cobalaminabhängigen Mutase aus Xanthobacter autotrophicus Py2.
SEQ ID NO: 7 und 8 zeigen die 1689 bzw. 408 bp der Nukleotidsequenz für die cobalaminabhängigen Mutasen aus Xanthobacter autotrophicus Py2.
SEQ ID NO: 5 and 6 show the amino acid sequences comprising 562 and 135 AA, respectively, of a cobalamin-dependent mutase from Xanthobacter autotrophicus Py2.
SEQ ID NO: 7 and 8 show the 1689 and 408 bp of the nucleotide sequence for the cobalamin-dependent mutases from Xanthobacter autotrophicus Py2.

SEQ ID NO: 9 und 10 zeigen die 563 bzw. 135 AS umfassenden Aminosäuresequenzen einer cobalaminabhängigen Mutase aus Rhodobacter sphaeroides ATCC 17029.
SEQ ID NO: 11 und 12 zeigen die 1692 bzw. 408 bp der Nukleotidsequenz für die cobalaminabhängigen Mutasen aus Rhodobacter sphaeroides ATCC 17029.
SEQ ID NOs: 9 and 10 show the 563 and 135 AA, respectively, amino acid sequences of a cobalamin-dependent mutase from Rhodobacter sphaeroides ATCC 17029.
SEQ ID NOs: 11 and 12 show the 1692 and 408 bp, respectively, of the nucleotide sequence for the cobalamin-dependent mutases from Rhodobacter sphaeroides ATCC 17029.

SEQ ID NO: 13 und 14 zeigen die 569 bzw. 164 AS umfassenden Aminosäuresequenzen einer cobalaminabhängigen Mutase aus Nocardoides sp. JS614.
SEQ ID NO: 15 und 16 zeigen die 1710 bzw. 495 bp der Nukleotidsequenz für die cobalaminabhängigen Mutasen aus Nocardoides sp. JS614.
SEQ ID NO: 13 and 14 show the 569 and 164 AS, respectively, amino acid sequences of a cobalamin-dependent mutase from Nocardoides sp. JS614.
SEQ ID NOS: 15 and 16 show the 1710 and 495 bp of the nucleotide sequence for the cobalamin-dependent mutases from Nocardoides sp. JS614.

Die erfindungsgemäß hergestellten 2-Hydroxy-2-methylcarbonsäuren können durch Behandlung des Kulturmediums (nach Entfernung von ungelösten Bestandteilen wie mikrobiellen Zellen) mit bereits bekannten Methoden isoliert werden. Solche Verfahren sind neben weiteren z. B. Konzentrierung, Ionenaustausch, Destillation, Elektrodialyse, Extraktion und Kristallisation. Das Produkt kann als Salz oder (nach Ansäuerung) als protonierte 2-Hydroxy-2-methylcarbonsäure isoliert werden.The 2-hydroxy-2-methylcarboxylic acids prepared according to the invention can be isolated by treatment of the culture medium (after removal of undissolved constituents such as microbial cells) by methods already known. Such methods are in addition to other z. As concentration, ion exchange, distillation, electrodialysis, extraction and crystallization. The product can be isolated as a salt or (after acidification) as a protonated 2-hydroxy-2-methylcarboxylic acid.

2-Hydroxy-2-methylcarbonsäuren (oder deren korrespondierende Salze) können durch eine Vielzahl von Verfahren zu den entsprechenden ungesättigten 2-Methylcarbonsäuren dehydratisiert werden. Zur Herstellung von C2-C3 ungesättigten Isoalkensäuren werden die hergestellten 2-Hydroxy-2-methylcarbonsäure nach den bekannten Verfahren des Standes der Technik dehydratisiert. Die Dehydratisierung der 2-Hydroxy-2-methylcarbonsäuren kann durch Einsatz von Metalloxiden, Metallhydroxiden, lonenaustauscherharzen, Tonerde, Siliziumdioxid, Aminen, Phosphinen, Alkalimetallalkoxiden und -carboxylaten erfolgen. Übliche Reaktionstemperaturen liegen zwischen 160 °C und 250 °C. So erfolgt z.B. die Herstellung von Methacrylsäure durch Dehydratisierung der 2-Hydroxyisobuttersäure in Gegenwart von NaOH, bei Temperaturen von ca. 185°C.2-Hydroxy-2-methylcarboxylic acids (or their corresponding salts) can be dehydrated by a variety of methods to the corresponding unsaturated 2-methylcarboxylic acids. For the preparation of C2-C3 unsaturated isoalkenoic acids, the produced 2-hydroxy-2-methylcarboxylic acid are dehydrated according to the known processes of the prior art. The dehydration of the 2-hydroxy-2-methylcarboxylic acids can be carried out by using metal oxides, metal hydroxides, ion exchange resins, alumina, silica, amines, phosphines, alkali metal alkoxides and carboxylates. Typical reaction temperatures are between 160 ° C and 250 ° C. For example, the Preparation of methacrylic acid by dehydration of 2-hydroxyisobutyric acid in the presence of NaOH, at temperatures of about 185 ° C.

Die durch diesen Prozess hergestellte Methacrylsäure und deren Homologe finden zweckdienliche Anwendung in einer ganzen Reihe von Industriezweigen, z. B. als Zusatzstoffe und in Beschichtungen. Die Methode vereinigt im Gegensatz zu den bisher bekannten Verfahren die gewünschten Vorteile eines Niedrigtemperatur-Prozesses, des Einsatzes von umweltunschädlichen Edukten und von geringer Abfallentstehung.The methacrylic acid and its homologs produced by this process find useful application in a whole range of industries, e.g. B. as additives and in coatings. The method combines in contrast to the previously known methods, the desired benefits of a low-temperature process, the use of environmentally harmful starting materials and low waste generation.

Anschließend wird die Erfindung an Ausführungsbeispielen näher beschrieben, auf die sie jedoch nicht beschränkt werden soll.Subsequently, the invention will be described in more detail in exemplary embodiments, to which, however, it should not be restricted.

Material und Methodenmaterial and methods Mikrobieller Enzym-KatalysatorMicrobial enzyme catalyst

Mikrobielle Zellen aus Stamm HCM-10 (DSM 18028), die durch eine 3-Hydroxycarbonyl-CoA-Ester produzierende und 3-Hydroxycarbonyl-CoA-Ester isomerisierende Aktivität charakterisiert sind oder die daraus isolierten Proteinuntereinheiten mit der Sequenz Nr. 2 und Nr. 4.Microbial cells from strain HCM-10 (DSM 18028) characterized by a 3-hydroxycarbonyl-CoA ester producing and 3-hydroxycarbonyl-CoA ester isomerizing activity or the isolated protein subunits with sequence no. 2 and no. 4 ,

Wachstum des mikrobiellen Enzym-KatalysatorsGrowth of the microbial enzyme catalyst

Der für die Herstellung von 2-Hydroxy-2-methylcarbonsäuren eingesetzte mikrobielle Stamm wurde wie unten beschrieben isoliert. Stammkulturen werden in 20 %iger Glyzerin-Lösung in flüssigem Stickstoff gelagert.The microbial strain used for the preparation of 2-hydroxy-2-methylcarboxylic acids was isolated as described below. Stock cultures are stored in 20% glycerol solution in liquid nitrogen.

Stamm HCM-10 wurde aus Grundwasser auf einem Basalmedium (Tab. 1) mit tert.-Butylalkohol als alleiniger Kohlenstoff- und Energiequelle angereichert. Phylogenetisch gehört der Stamm zur Rubrivivax-Leptothrix-Gruppe. Tabelle 1 Basalmedium (mg/L) NH4C1 761,4 Biotin 0,02 KH2PO4 340,25 Folsäure 0,02 K2HPO4 435,45 Pyridoxin-HCl 0,1 CaCl2 x 6 H2O 5,47 Thiamin-HCl 0,05 MgSO4 x 7 H2O 71,2 Riboflavin 0,05 ZnSO4 x 7 H2O 0,44 Nicotinsäure 0,05 MnSO4 x H2O 0,615 DL-Ca-Pantothenat 0,05 CuSO4 x 5 H2O 0,785 p-Aminobenzoesäure 0,05 CoCl2 x 6 H2O 0,2 Liponsäure 0,05 Na2MoO4 x 2 H2O 0,252 FeSO4 x 7 H2O 4,98 pH 7,0 Strain HCM-10 was enriched from groundwater on a basal medium (Table 1) with tert-butyl alcohol as the sole source of carbon and energy. Phylogenetically, the strain belongs to the Rubrivivax-leptothrix group. <b> Table 1 </ b> Basal medium (mg / L) NH 4 C1 761.4 biotin 0.02 KH 2 PO 4 340.25 folic acid 0.02 K 2 HPO 4 435.45 Pyridoxine HCl 0.1 CaCl 2 × 6 H 2 O 5.47 Thiamine HCl 0.05 MgSO 4 × 7H 2 O 71.2 riboflavin 0.05 ZnSO 4 × 7H 2 O 0.44 nicotinic acid 0.05 MnSO 4 × H 2 O 0.615 DL-Ca pantothenate 0.05 CuSO 4 × 5 H 2 O 0,785 p-aminobenzoic acid 0.05 CoCl 2 × 6 H 2 O 0.2 lipoic acid 0.05 Na 2 MoO 4 × 2 H 2 O 0.252 FeSO 4 × 7 H 2 O 4.98 pH 7.0

Stamm HCM-1 0 wurde aerob unter den folgenden Bedingungen (Tab. 2) zum Testen der 3-Hydroxycarbonyl-CoA-Mutase-Aktivität angezogen. Tabelle 2 Stamm Substrat Medium Temperatur (°C) Dauer (d) HCM-10 tert.-Butylalkohol (0,5 g/L) Basalmedium 25 7 Strain HCM-1 0 was grown aerobically under the following conditions (Table 2) for testing 3-hydroxycarbonyl-CoA mutase activity. <b> Table 2 </ b> tribe substratum medium Temperature (° C) Duration (d) HCM-10 tert-butyl alcohol (0.5 g / L) basal 25 7

Zellen wurden unmittelbar nach der Ernte eingesetzt. Intakte Zellen können ohne weitere Vorbehandlung, wie z. B. Permeabilisierung, eingesetzt werden. Außerdem können die Zellen permeabilisiert verwendet werden (z. B. durch Behandlung mit Toluen, Detergenzien oder durch Gefrier-Auftau-Zyklen), um die Diffusionsraten von Stoffen in die Zellen hinein und aus den Zellen hinaus zu verbessern.Cells were used immediately after harvest. Intact cells can without further pretreatment, such. B. permeabilization, are used. In addition, the cells may be used permeabilized (eg, by treatment with toluene, detergents, or by freeze-thaw cycles) to enhance the diffusion rates of substances into and out of the cells.

Die Konzentration der 2-Hydroxyisobuttersäure und 3-Hydroxybuttersäure in der Kulturflüssigkeit bzw. im Reaktionsansatz wurden durch Gaschromatographie nach saurer Methanolyse unter Nutzung einer FFAP Säule und eines FID Detektors bestimmt.The concentration of 2-hydroxyisobutyric acid and 3-hydroxybutyric acid in the culture liquid or in the reaction mixture were by gas chromatography acid methanolysis using a FFAP column and a FID detector.

Beispiel 1:Example 1: Konversion von 3-Hydroxybuttersäure in 2-Hydroxyisobuttersäure durch Stamm HCM-10Conversion of 3-hydroxybutyric acid into 2-hydroxyisobutyric acid by strain HCM-10

Eine Suspension von 1 g (Trockengewicht) Zellen von Stamm HCM-10 in 100 mL Basalmedium wurde in 120-mL-Serumflaschen gefüllt. Zu dieser Suspension wurden 50 mg 3-Hydroxybuttersäure gegeben und die Suspension auf einem rotierenden Schüttler bei 30°C inkubiert. Nach 0,3 h aerober Inkubation wurde die Suspension mit Stickstoff begast und weitere 4,4 h bei 30°C unter Schütteln inkubiert. Zu verschiedenen Zeiten wurden Proben genommen und der Gehalt an 2-Hydroxyisobuttersäure und 3-Hydroxybuttersäure im zellfreien Überstand nach Zentrifugation der Suspension bestimmt. 2-Hydroxyisobuttersäure wurde als alleiniges Produkt festgestellt, das in der anaeroben Phase freigesetzt wurde. In der aeroben initialen Phase wurde 3-Hydroxybuttersäure dagegen offensichtlich komplett abgebaut (Abb. 1). Die Ausbeute an 2-Hydroxyisobuttersäure war in diesem Fall 5,1 %, ca. 80 % der 3-Hydroxybuttersäure verblieben in der Reaktionsflüssigkeit.A suspension of 1 g (dry weight) cells of strain HCM-10 in 100 mL basal medium was filled in 120 mL serum bottles. To this suspension, 50 mg of 3-hydroxybutyric acid were added and the suspension was incubated on a rotating shaker at 30 ° C. After 0.3 h aerobic incubation, the suspension was gassed with nitrogen and incubated for a further 4.4 h at 30 ° C with shaking. Samples were taken at various times and the content of 2-hydroxyisobutyric acid and 3-hydroxybutyric acid in the cell-free supernatant determined after centrifuging the suspension. 2-hydroxyisobutyric acid was found to be the sole product released in the anaerobic phase. In the aerobic initial phase, however, 3-hydroxybutyric acid was apparently completely degraded ( Fig. 1 ). The yield of 2-hydroxyisobutyric acid in this case was 5.1%, about 80% of the 3-hydroxybutyric acid remained in the reaction liquid.

Beispiel 2:Example 2: Konversion von 3-Hydroxybuttersäure in 2-Hydroxyisobuttersäure durch Rohextrakt von Stamm HCM-10Conversion of 3-hydroxybutyric acid into 2-hydroxyisobutyric acid by crude extract of strain HCM-10

Zellfreier Rohextrakt von Stamm HCM-10 wurde durch Desintegration der Zellen in einer Kugelmühle hergestellt, Zellbruchstücke wurden nachfolgend durch Zentrifugation abgetrennt. Zellfreier Rohextrakt in einer Konzentration von 10 mg Protein in 5 mL 50-mM-Kaliumphosphatpuffer (enthält 1 mM MgCl2 bei pH 7,2) wurde in verschließbare 10-mL-Glasgefäße gegeben. Diesem Extrakt wurde im Weiteren 0,01 mM Coenzym B12, 1 mM CoenzymA, 1 mM ATP und 4,25 mg 3-Hydroxybuttersäure zugesetzt. Die Reaktionsflüssigkeit wurde mit Stickstoff begast, das Reaktionsgefäß dicht verschlossen und unter Schütteln 2 h bei 30°C inkubiert. Die Reaktionsprodukte wurden wie oben gezeigt analysiert. Die Ausbeute an 2-Hydroxyisobuttersäure war in diesem Fall 9 %, ca. 88 % der 3-Hydroxybuttersäure verblieben in der Reaktionsflüssigkeit (Abb. 2).Cell-free crude extract of strain HCM-10 was prepared by disintegration of the cells in a ball mill, cell debris was subsequently separated by centrifugation. Cell-free crude extract at a concentration of 10 mg protein in 5 mL 50 mM potassium phosphate buffer (containing 1 mM MgCl 2 at pH 7.2) was placed in 10 mL closable glass jars. To this extract was further added 0.01 mM coenzyme B12, 1 mM coenzyme A, 1 mM ATP and 4.25 mg 3-hydroxybutyric acid. The reaction liquid was gassed with nitrogen, the reaction vessel sealed and incubated with shaking at 30 ° C for 2 h. The reaction products were analyzed as shown above. The yield of 2-hydroxyisobutyric acid was 9% in this case, about 88% of the 3-hydroxybutyric acid remained in the reaction liquid ( Fig. 2 ).

Beispiel 3:Example 3: Dehydratisierung von 2-Hydroxyisobuttersäure zu MethacrylatDehydration of 2-hydroxyisobutyric acid to methacrylate

Eine Lösung von 2-Hydroxyisobuttersäure (1 mg/5 mL), produziert entspr. der in Beispiel 2 ausgeführten Prozedur wurde unter Rühren mit NaOH (0.06 mg) versetzt. Die Lösung wurde unter Rührung und Rückflusskühlung bei 185-195°C unter Vakuum (300 torr) inkubiert. Über einen Zeitraum von 5 h wurden stündlich weitere Aliquote von 0.5 mg 2-Hydroxyisobuttersäure pro 5 mL zugesetzt, diese enthielten zusätzlich 0.4 Gewichtsprozent p-Methoxyphenol, um ein Polymerisieren von Methacrylat zu verhindern. Nach 24 h Inkubation wurde die Reaktion beendet. Der Umsatz an 2-Hydroxyisobuttersäure zu Methacrylat belief sich auf 97%. Die Abtrennung von Methacrylsäure aus dem Reaktionsansatz erfolgte durch Destillation.A solution of 2-hydroxyisobutyric acid (1 mg / 5 mL), produced according to the procedure set forth in Example 2, was added NaOH (0.06 mg) with stirring. The solution was incubated with stirring and refluxing at 185-195 ° C under vacuum (300 torr). Over a period of 5 h, additional aliquots of 0.5 mg of 2-hydroxyisobutyric acid per 5 mL were added per hour, which additionally contained 0.4 percent by weight of p-methoxyphenol to prevent polymerization of methacrylate. After 24 h of incubation, the reaction was stopped. The conversion of 2-hydroxyisobutyric acid to methacrylate amounted to 97%. The separation of methacrylic acid from the reaction mixture was carried out by distillation.

Anhang SequenzenAttachment sequences

  • Sequenz Nr. 1 - 1644 bp (HCM-10; DSM 18028)
    Figure imgb0002
    Sequence No. 1-1644 bp (HCM-10; DSM 18028)
    Figure imgb0002
  • Sequenz Nr. 2 - 548 aa (HCM-10; DSM 18028)
    Figure imgb0003
    Sequence No. 2 - 548 aa (HCM-10; DSM 18028)
    Figure imgb0003
  • Sequenz Nr. 3 - 370 bp (HCM-10; DSM 18028)
    Figure imgb0004
    Sequence No. 3 - 370 bp (HCM-10; DSM 18028)
    Figure imgb0004
  • Sequenz Nr. 4 -123 aa (HCM-10; DSM 18028)
    Figure imgb0005
    Sequence No. 4 -123 aa (HCM-10; DSM 18028)
    Figure imgb0005
  • Sequenz Nr. 7 - 1689 bp DNA, Xanthobacter autotrophicus Py2
    NZU_AAPC01000001.1:231146..232834 (mit Sequenz 1 von HCM-10: Identität = 1283/1598 (80%), Gaps = 0/1598 (0%))
    Figure imgb0006
    Sequence No. 7 - 1689 bp DNA, Xanthobacter autotrophicus Py2
    NZU_AAPC01000001.1: 231146..232834 (with Sequence 1 of HCM-10: Identity = 1283/1598 (80%), Gaps = 0/1598 (0%))
    Figure imgb0006
  • Sequenz Nr. 5 - 562 aa, Xanthobacter autotrophicus Py2
    ZP_01195960; (mit Sequenz 2 von HCM-10: Identität = 445/547 (81%), Positives = 492/547 (89%), Gaps = 0/547 (0%))
    Figure imgb0007
    Sequence No. 5 - 562 aa, Xanthobacter autotrophicus Py2
    ZP_01195960; (with sequence 2 of HCM-10: identity = 445/547 (81%), positive = 492/547 (89%), gaps = 0/547 (0%))
    Figure imgb0007
  • Sequenz Nr. 8; 408bp DNA, Xanthobacter autotrophicus Py2
    NZ_AAPC01000001.1:235266..235673; (mit Sequenz 3 von HCM-10: Identität = 226/274 (82%), Gaps = 0/274 (0%))
    Figure imgb0008
    Sequence no. 8; 408bp DNA, Xanthobacter autotrophicus Py2
    NZ_AAPC01000001.1: 235266..235673; (with Sequence 3 of HCM-10: identity = 226/274 (82%), Gaps = 0/274 (0%))
    Figure imgb0008
  • Sequenz Nr. 6, 135 aa, Xanthobacter autotrophicus Py2
    ZP_01195963; (mit Sequenz 4 von HCM-10: Identität = 102/123 (82%), Positives = 114/123 (92%), Gaps = 0/123(0%))
    Figure imgb0009
    Sequence No. 6, 135 aa, Xanthobacter autotrophicus Py2
    ZP_01195963; (with sequence 4 of HCM-10: identity = 102/123 (82%), positive = 114/123 (92%), gaps = 0/123 (0%))
    Figure imgb0009
  • Sequenz Nr. 11, 1692 bp DNA, Rhodobacter sphaeroides ATCC 17029
    NZ_AAMF01000011.1:59715..61406; (mit Sequenz 1 von HCM-10: Identität = 1302/1568 (83%), Gaps = 011568 (0%))
    Figure imgb0010
    Sequence No. 11, 1692 bp DNA, Rhodobacter sphaeroides ATCC 17029
    NZ_AAMF01000011.1: 59715..61406; (with sequence 1 of HCM-10: identity = 1302/1568 (83%), gaps = 011568 (0%))
    Figure imgb0010
  • Sequenz Nr. 9, 563 aa, Rhodobacter sphaeroides ATCC 17029
    ZP_00919811; (mit Sequenz 2 von HCM-10: Identität = 451/540 (83%), Positives = 499/540 (92%), Gaps = 0/540 (0%))
    Figure imgb0011
    Sequence No. 9,563a, Rhodobacter sphaeroides ATCC 17029
    ZP_00919811; (with sequence 2 of HCM-10: identity = 451/540 (83%), positive = 499/540 (92%), gaps = 0/540 (0%))
    Figure imgb0011
  • Sequenz Nr. 12, 408 bp DNA, Rhodobacter sphaeroides ATCC 17029
    NZ_AAMF01000011.1:63815..64222; (mit Sequenz 3 von HCM-10: Identität = 259/345 (75%), Gaps = 0/345 (0%))
    Figure imgb0012
    Figure imgb0013
    Sequence No. 12, 408 bp DNA, Rhodobacter sphaeroides ATCC 17029
    NZ_AAMF01000011.1: 63815..64222; (with sequence 3 of HCM-10: identity = 259/345 (75%), gaps = 0/345 (0%))
    Figure imgb0012
    Figure imgb0013
  • Sequenz Nr. 10, 135 aa, Rhodobacter sphaeroides ATCC 17029
    ZP_00919814, (mit Sequenz 4 von HCM-10: Identität = 96/123 (78%), Positives = 107/123 (86%), Gaps = 0/123 (0%))
    Figure imgb0014
    Sequence No. 10, 135 aa, Rhodobacter sphaeroides ATCC 17029
    ZP_00919814, (with sequence 4 of HCM-10: identity = 96/123 (78%), positive = 107/123 (86%), gaps = 0/123 (0%))
    Figure imgb0014
  • Sequenz Nr. 15, 1710 bp DNA, Nocardioides sp. JS614
    NZ_AAJB01000007.1:74197..75906; (mit Sequenz 1 von HCM-10: Identität = 775/1059 (73%), Gaps =0/1059 (0%))
    Figure imgb0015
    Sequence # 15, 1710 bp DNA, Nocardioides sp. JS614
    NZ_AAJB01000007.1: 74197..75906; (with Sequence 1 of HCM-10: identity = 775/1059 (73%), Gaps = 0/1059 (0%))
    Figure imgb0015
  • Sequenz Nr. 13, 569 aa, Nocardioides sp. JS614
    ZP_00656557; (mit Sequenz 2 von HCM-10: Identität = 341/538 (63%), Positives = 421/538 (78%), Gaps = 1/538 (0%))
    Figure imgb0016
    Figure imgb0017
    Sequence No. 13,569a, Nocardioides sp. JS614
    ZP_00656557; (with sequence 2 of HCM-10: identity = 341/538 (63%), positive = 421/538 (78%), gaps = 1/538 (0%))
    Figure imgb0016
    Figure imgb0017
  • Sequenz Nr. 16, 495 bp DNA, Nocardioides sp. JS614
    NZ_AAJB01000007.1:78317..78811: (mit Sequenz 3 von HCM-10: Identität = 138/173 (79%), Gaps = 0173 (0%))
    Figure imgb0018
    Sequence No. 16, 495 bp DNA, Nocardioides sp. JS614
    NZ_AAJB01000007.1: 78317..78811: (with Sequence 3 of HCM-10: Identity = 138/173 (79%), Gaps = 0173 (0%))
    Figure imgb0018
  • Sequenz Nr. 14, 164 aa, Nocardioides sp. JS614
    ZP_00656560; (mit Sequenz 4 von HCM-10: Identität = 72/120 (60%), Positives = 94/120 (78%), Gaps = 1/120 (0%))
    Figure imgb0019
    Sequence No. 14, 164 aa, Nocardioides sp. JS614
    ZP_00656560; (with sequence 4 of HCM-10: identity = 72/120 (60%), positive = 94/120 (78%), gaps = 1/120 (0%))
    Figure imgb0019

Claims (29)

  1. Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids from 3-hydroxy carboxylic acids, characterized in that a 3-hydroxy carboxylic acid is produced in and/or added to an aqueous reaction solution comprising a unit having 3-hydroxy-carboxylate-C o A mutase activity, which has both 3-hydroxy-carbonyl-CoA ester-producing and 3-hydroxy-carbonyl-CoA ester-isomerizing activity, and, after incubation, the correspondingly converted 2-hydroxy-2-methyl carboxylic acid is isolated as acid or in the form of its salts.
  2. Method according to Claim 1, characterized in that the unit having 3-hydroxy-carboxylate-CoA mutase activity comprises an isolated cobalamin-dependent mutase.
  3. Method according to Claim 1 or 2, characterized in that the unit having 3-hydroxy-carboxylate-CoA mutase activity comprises a 3-hydroxy-carbonyl-CoA ester-producing enzyme or enzyme system.
  4. Method according to any of Claims 1 to 3, characterized in that the unit having 3-hydroxy-carboxylate-CoA mutase activity is a microorganism or a crude extract thereof.
  5. Method according to Claim 1 or 4, characterized in that microorganisms producing or comprising a cobalamin-dependent mutase, having 3-hydroxy-carboxylate-CoA mutase activity and having both 3-hydroxy-carbonyl-CoA ester-producing and 3-hydroxy-carbonyl-CoA ester-isomerizing activity are used in aqueous systems for converting 3-hydroxy carboxylic acids to the corresponding 2-hydroxy-2-methyl carboxylic acid.
  6. Method according to any of Claims 1 to 5, characterized in that
    a) microorganisms with 3-hydroxy-carboxylate-CoA mutase activity, which have both 3-hydroxy-carbonyl-CoA thioester-producing activity and 3-hydroxy-carbonyl-CoA thioester-isomerizing activity, are cultured in an aqueous system with renewable raw materials or waste products deriving from the consumption of renewable raw materials as carbon and energy sources, whereby intracellular 3-hydroxy-carboxylate-CoA thioesters are synthesized and converted to the corresponding 2-hydroxy-2-methyl carboxylic acids, and
    b) the corresponding 2-hydroxy-2-methyl carboxylic acid is isolated as acid or in the form of its salts.
  7. Method according to any of Claims 1 to 6, characterized in that the reaction is carried out with the addition of external 3-hydroxy carboxylic acid.
  8. Method according to any of Claims 1 to 7, characterized in that the microorganism is selected from bacterial strain HCM-10 DSM 18028, Xanthobacter autotrophicus Py2, Rhodobacter sphaeroides (ATCC17029) or Nocardioides sp. JS614.
  9. Method according to any of Claims 1 to 8, characterized in that intact cells of the microorganisms are used unchanged, permeabilized or fixed to a support.
  10. Method according to any of Claims 1 to 8, characterized in that cell extracts and/or the cobalamin-dependent mutase and, where appropriate, the other enzymes such as, for example, CoA ester-synthesizing enzymes, after partial or complete isolation from the microorganisms are used, where appropriate in a purified form.
  11. Method according to Claim 10, characterized in that cell-free crude extracts of the microorganisms are used.
  12. Method according to any of Claims 1 to 11, characterized in that the proteins with the sequences SEQ ID NO: 2 and/or SEQ ID NO: 4, with the sequences SEQ ID NO: 5 and/or SEQ ID NO: 6, the proteins with the sequences SEQ ID NO: 9 and/or SEQ ID NO: 10, or the proteins with the sequences SEQ ID NO: 13 and/or SEQ ID NO: 14, are used, and also their at least 60% homologues.
  13. Method according to any of Claims 1 to 12, characterized in that a sugar and/or an alcohol and/or an organic acid and/or a hydrocarbon or their derivatives are used as carbon and energy sources for enzymatic conversion during culturing.
  14. Method according to any of Claims 1 to 13, characterized in that a substrate with a tert-butyl radical is used as carbon source and energy source for culturing.
  15. Method according to any of Claims 1 to 14, characterized in that tert-butyl alcohol is used as sole carbon source and energy source in a basal medium for culturing.
  16. Method according to any of Claims 1 to 15, characterized in that the enzymatic conversion of a sugar and/or an alcohol and/or an organic acid and/or a hydrocarbon or their derivatives to the 3-hydroxy carboxylic acid and of the 3-hydroxy carboxylic acid to the 2-hydroxy-2-methyl carboxylic acid is carried out in a single method step.
  17. Method according to any of Claims 1 to 16, characterized in that 2-hydroxy isobutyric acid is produced with the addition of external 3-hydroxy butyric acid.
  18. Method for the production of C2-C3-unsaturated isoalkenoic acids, characterized in that a 2-hydroxy-2-methyl carboxylic acid is produced according to a method according to any of Claims 1 to 17 and is then dehydrated.
  19. Method for the production of methacrylic acid, characterized in that a 2-hydroxy isobutyric acid is produced according to a method according to any of Claims 1 to 17 and is then dehydrated.
  20. Microorganism strain HCM-10 - DSM 18028.
  21. Nucleic acid molecule coding for an enzyme having the activity of a cobalamin-dependent mutase, selected from the group consisting of
    a) nucleic acid molecules coding for a protein comprising the amino acid sequences indicated under Seq. No. 2 and/or Seq. No. 4;
    b) nucleic acid molecules comprising the nucleotide sequence depicted under Seq. No. 1 and/or Seq. No. 3.
  22. Nucleic acid molecule according to Claim 21, characterized in that it codes for a protein which, as an oligomeric enzyme composed of two different subunits, comprises the amino acid sequences indicated under Seq. No. 2 and Seq. No. 4.
  23. Nucleic acid molecule according to Claim 21 or 22, which is a DNA molecule.
  24. Nucleic acid molecule according to Claim 23, which is a cDNA or genomic DNA.
  25. Nucleic acid molecule according to Claim 21 or 22, which is an RNA molecule.
  26. Protein having the activity of a cobalamin-dependent mutase encoded by a nucleic acid molecule according to Claims 21 to 22.
  27. Protein with the sequence No. 2.
  28. Protein with the sequence No. 4 and its at least 99% homologues.
  29. Protein as heterodimeric enzyme comprising sequence No. 2 and sequence No. 4.
EP07727304A 2006-03-24 2007-03-23 Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids Not-in-force EP1999264B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006014167 2006-03-24
DE102006017760A DE102006017760A1 (en) 2006-03-24 2006-04-12 Enzymatic preparation of 2-hydroxy-2-methylcarboxylic acid comprises producing 3-hydroxycarboxylic acid in aqueous reaction solution, incubating the obtained solution and converting to 2-hydroxy-2-methylcarboxylic acid
PCT/EP2007/052830 WO2007110394A2 (en) 2006-03-24 2007-03-23 Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids

Publications (2)

Publication Number Publication Date
EP1999264A2 EP1999264A2 (en) 2008-12-10
EP1999264B1 true EP1999264B1 (en) 2010-05-12

Family

ID=38438483

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07727304A Not-in-force EP1999264B1 (en) 2006-03-24 2007-03-23 Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids

Country Status (13)

Country Link
US (2) US7923225B2 (en)
EP (1) EP1999264B1 (en)
JP (1) JP2009538118A (en)
KR (1) KR20090005052A (en)
AT (1) ATE467684T1 (en)
AU (1) AU2007229522A1 (en)
BR (1) BRPI0709142B1 (en)
CA (1) CA2653028C (en)
DE (2) DE102006017760A1 (en)
MX (1) MX2008012233A (en)
NO (1) NO20084416L (en)
RU (1) RU2459871C2 (en)
WO (1) WO2007110394A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012216904A1 (en) * 2012-09-20 2014-03-20 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz Process for the isomerization of (R) -3-hydroxycarboxylic acids to 2-hydroxy-2-methylcarboxylic acids

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006017760A1 (en) * 2006-03-24 2007-09-27 Ufz-Umweltforschungszentrum Leipzig-Halle Gmbh Enzymatic preparation of 2-hydroxy-2-methylcarboxylic acid comprises producing 3-hydroxycarboxylic acid in aqueous reaction solution, incubating the obtained solution and converting to 2-hydroxy-2-methylcarboxylic acid
DE102006025821A1 (en) * 2006-06-02 2007-12-06 Degussa Gmbh An enzyme for the production of Mehylmalonatsemialdehyd or Malonatsemialdehyd
DE102007060705A1 (en) 2007-12-17 2009-06-18 Evonik Degussa Gmbh ω-aminocarboxylic acids or their lactams, producing, recombinant cells
JP5755884B2 (en) 2008-03-05 2015-07-29 ジェノマティカ, インコーポレイテッド Living organisms that produce primary alcohol
WO2009135074A2 (en) 2008-05-01 2009-11-05 Genomatica, Inc. Microorganisms for the production of methacrylic acid
DE102008002715A1 (en) * 2008-06-27 2009-12-31 Evonik Röhm Gmbh 2-hydroxyisobutyric acid producing recombinant cell
DE102008040193A1 (en) 2008-07-04 2010-01-07 Evonik Röhm Gmbh Process for the preparation of free carboxylic acids
WO2010022763A1 (en) * 2008-08-25 2010-03-04 Metabolic Explorer Method for the preparation of 2-hydroxy-isobutyrate
DE102009029651A1 (en) 2009-09-22 2011-03-24 Evonik Röhm Gmbh Process for the preparation of free carboxylic acids
DE102009046623A1 (en) * 2009-11-11 2011-05-12 Evonik Röhm Gmbh Use of a protein homologous to a MeaB protein to increase the enzymatic activity of a 3-hydroxycarboxylic acid CoA mutase
US8637286B2 (en) * 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
DE102010015807A1 (en) 2010-04-20 2011-10-20 Evonik Degussa Gmbh Biocatalytic oxidation process with alkL gene product
KR101990014B1 (en) * 2010-10-28 2019-06-17 아디쎄오 프랑스 에스에이에스 A method of production of 2,4-dihydroxybutyric acid
US9580732B2 (en) 2011-07-20 2017-02-28 Evonik Degussa Gmbh Oxidation and amination of primary alcohols
EP2602328A1 (en) 2011-12-05 2013-06-12 Evonik Industries AG Method of Oxidation of alkanes employing an AlkB alkane 1-monooxygenase
EP2607490A1 (en) 2011-12-22 2013-06-26 Evonik Industries AG Method for improved separation of a hydrophobic organic solution from an aqueous culture medium
EP2607479A1 (en) 2011-12-22 2013-06-26 Evonik Industries AG Biotechnological production of alcohols and derivatives thereof
EP2631298A1 (en) 2012-02-22 2013-08-28 Evonik Industries AG Biotechnological method for producing butanol and butyric acid
EP2639308A1 (en) 2012-03-12 2013-09-18 Evonik Industries AG Enzymatic omega-oxidation and -amination of fatty acids
EP2647696A1 (en) 2012-04-02 2013-10-09 Evonik Degussa GmbH Method for aerobic production of alanine or a compound arising using alanine
DE102012207921A1 (en) 2012-05-11 2013-11-14 Evonik Industries Ag Multi-stage synthesis process with synthesis gas
EP2674489A1 (en) * 2012-06-15 2013-12-18 Evonik Industries AG Biotechnological 2-hydroxyisobutyric acid production
EP2706076B1 (en) 2012-09-07 2014-12-17 Evonik Industries AG Hardening compounds on the basis of epoxide resins without benzyl alcohol
WO2014038216A1 (en) 2012-09-10 2014-03-13 三菱レイヨン株式会社 Method for producing methacrylic acid and/or ester thereof
JP6146308B2 (en) 2012-09-10 2017-06-14 三菱ケミカル株式会社 Method for producing methacrylate ester
EP2746397A1 (en) 2012-12-21 2014-06-25 Evonik Industries AG Production of omega amino fatty acids
EP2759598A1 (en) 2013-01-24 2014-07-30 Evonik Industries AG Process for preparing alpha, omega alkanediols
DE102013202106A1 (en) 2013-02-08 2014-08-14 Evonik Industries Ag Autotrophic cultivation
DE102014201579B4 (en) * 2013-02-13 2017-06-14 Ford Global Technologies, Llc Internal combustion engine with selective catalyst for reducing nitrogen oxides and method for operating such an internal combustion engine
BR112016000541B1 (en) 2013-08-01 2023-01-10 Mitsubishi Chemical Corporation METHOD FOR PRODUCTION OF METHACRYL-COA AND CONVERSION OF METHACRYL-COA INTO METHACRYL ACID OR METHACRYLATE ESTER
JP6202772B2 (en) 2013-08-26 2017-09-27 スティヒティング ディーンスト ランドバウクンディフ オンデルズーク Process for the production of methacrylic acid
DE102014201384A1 (en) 2014-01-27 2015-07-30 Evonik Industries Ag A method comprising low dissolved oxygen concentration culture
AU2015225348B2 (en) 2014-03-07 2017-06-08 Mitsubishi Chemical Corporation Method for producing methacrylic acid ester, and novel methacrylic acid ester synthase
DE102015201531A1 (en) 2014-04-14 2015-10-15 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz A method for changing the specificity of a cobalamin-dependent 2-hydroxyisobutyl CoA mutase
DE102014218121A1 (en) 2014-09-10 2016-03-10 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz Process for the enzymatic preparation of 2-hydroxycarboxylic acids
RU2743228C2 (en) * 2015-06-25 2021-02-16 Дайнамик Фуд Ингридиентс Корпорейшн Method for production of 2,4-dihydroxybutyric acid
MY184030A (en) 2015-10-23 2021-03-17 Univ California Biological production of methyl methacrylate
EP3746559A4 (en) 2018-02-01 2021-12-22 INVISTA Textiles (U.K.) Limited Methods and materials for the biosynthesis of beta hydroxy fatty acid anions and/or derivatives thereof and/or compounds related thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH455748A (en) * 1965-03-12 1968-05-15 Lonza Ag Process for the production of methacrylic acid from α-oxyisobutyric acid
JP2926354B2 (en) * 1990-06-08 1999-07-28 三菱レイヨン株式会社 Biological production of α-hydroxyisobutyric acid
JP2959121B2 (en) 1990-11-28 1999-10-06 三菱瓦斯化学株式会社 Method for producing methacrylic acid
US6582943B1 (en) 2002-02-05 2003-06-24 E. I. Du Pont De Nemours And Company Method for producing 2-hydroxyisobutyric acid and methacrylic acid from acetone cyanohydrin
JP4040897B2 (en) 2002-04-03 2008-01-30 ローランドディー.ジー.株式会社 Dust collection mechanism in printed circuit board divider
DE102006017760A1 (en) 2006-03-24 2007-09-27 Ufz-Umweltforschungszentrum Leipzig-Halle Gmbh Enzymatic preparation of 2-hydroxy-2-methylcarboxylic acid comprises producing 3-hydroxycarboxylic acid in aqueous reaction solution, incubating the obtained solution and converting to 2-hydroxy-2-methylcarboxylic acid
DE102006025821A1 (en) 2006-06-02 2007-12-06 Degussa Gmbh An enzyme for the production of Mehylmalonatsemialdehyd or Malonatsemialdehyd
DE102007015583A1 (en) 2007-03-29 2008-10-02 Albert-Ludwigs-Universität Freiburg An enzyme for the production of methylmalonyl-coenzyme A or ethylmalonyl-coenzyme A and its use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012216904A1 (en) * 2012-09-20 2014-03-20 Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz Process for the isomerization of (R) -3-hydroxycarboxylic acids to 2-hydroxy-2-methylcarboxylic acids

Also Published As

Publication number Publication date
DE102006017760A1 (en) 2007-09-27
US8349596B2 (en) 2013-01-08
DE502007003734D1 (en) 2010-06-24
NO20084416L (en) 2008-12-19
AU2007229522A1 (en) 2007-10-04
RU2459871C2 (en) 2012-08-27
BRPI0709142A2 (en) 2011-06-28
KR20090005052A (en) 2009-01-12
WO2007110394A2 (en) 2007-10-04
US20110165640A1 (en) 2011-07-07
JP2009538118A (en) 2009-11-05
MX2008012233A (en) 2008-12-10
RU2008142188A (en) 2010-04-27
WO2007110394A3 (en) 2008-03-06
CA2653028A1 (en) 2007-10-04
ATE467684T1 (en) 2010-05-15
CA2653028C (en) 2015-05-26
BRPI0709142B1 (en) 2017-02-21
US7923225B2 (en) 2011-04-12
US20100035314A1 (en) 2010-02-11
EP1999264A2 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
EP1999264B1 (en) Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids
DE102011100772A1 (en) Process for the preparation of isomaltulose from plant juices
DE102009002583A1 (en) Cells and processes for the production of acetone
DE102008029302B4 (en) Biotechnological production of acrylic acid
EP1437415A1 (en) Preparation of lactic acid from a pentose-containing substrate
EP0347374B1 (en) Process for the preparation of hydroxy acids
DE10129711A1 (en) Process for the fermentative production of pyruvate
EP2143785A1 (en) Method for producing glucuronic acid by glucuronic acid fermentation
DE2757980C2 (en)
EP0502525B1 (en) Biotechnological process for the production of S-(+)-2,2-dimethylcyclopropanecarboxamide and R-(-)-2,2-dimethylcyclopropanecarboxylic acid
US7083955B2 (en) Preparation of lactic acid from a pentose-containing substrate
AU597264B2 (en) Fermentation process for the production of fructose from aqueous mixtures of fructose and glucose and zymomonas mobilis mutants which can be used for such fermentation
EP2193194B1 (en) Method for producing 2-methyl-1,2-dihydroxypropane
DE69801789T2 (en) Process for the preparation of optically active 1,2,4-butanetriols
JP2973669B2 (en) Process for producing (S)-(-)-2,3-dihalo-1-propanol
Tangri et al. Improvement in xylitol production from wheat straw hemicellulosic hydrolysate achieved by the use of immobilized Aspergillus terreus cells
JPH10210994A (en) Production of ribitol
JPH02207783A (en) Culture of phodococcus bacteria and production of 2-ketobutyric acid using same
DE102007045092A1 (en) Enzyme system with the activity of a monooxygenase and method for the oxidation of methyl groups in aliphatic hydrocarbons
DD266117A1 (en) METHOD FOR PRODUCING INVERT SUGAR

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080922

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090619

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 502007003734

Country of ref document: DE

Date of ref document: 20100624

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100512

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100823

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100912

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100913

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

26N No opposition filed

Effective date: 20110215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100813

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502007003734

Country of ref document: DE

Effective date: 20110214

BERE Be: lapsed

Owner name: EVONIK ROHM G.M.B.H.

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110323

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110323

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 467684

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100812

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100512

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180322

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502007003734

Country of ref document: DE

Owner name: ROEHM GMBH, DE

Free format text: FORMER OWNER: EVONIK ROEHM GMBH, 64293 DARMSTADT, DE

Ref country code: DE

Ref legal event code: R119

Ref document number: 502007003734

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191001